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“Anything the mind of man can conceive and believe, it can be achieved”
                  Napoleon Hill
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ABSTRACT
Intracerebral hemorrhage (ICH) represents the subtype of stroke carrying the 
most detrimental outcome and highest mortality. It is clearly underinvesti-
gated and lacks an effective treatment except supportive management measures. 
The dismal outcomes of ICH are clearly associated with the mass effect of 
hematoma accompanied with dynamic perihematomal edema (PHE) and potential 
intraventricular bleeding (IVH), which is often complicated by development of 
hydrocephalus. 
In this thesis, we aimed to develop novel therapy modalities, which apart from 
experimental conditions, might be found effective in clinical scenario, and 
successfully implemented in ICH treatment clinical protocols in the future.
In study (I), we utilized autologous blood injection model and magnetic resonance 
imaging (MRI) follow-up. Following the induction of deep right hemispheric 
hematoma of 75 mL of volume, we performed decompressive craniectomy (DC) 
at 1 h, 6 h, and 24 h time points, aiming at diminishing high intracranial pressure 
(ICP) after the bleeding event. Control group did not undergo DC procedure. 
Decompressive craniectomy was found effective in reducing mortality and 
improving overall neurobehavioral outcome and mortality in all the 3 treatment 
groups. Effect of DC was most pronounced in the early craniectomy group (1 h).
In study (II), we aimed to examine how deleterious is the influence of tissue 
plasminogen activator (tPA) in experimental ICH scenario, and whether the 
adverse tPA effects could be antagonized by the clinically safe mast-cell stabilizer 
chromoglycate. Animals were divided in four groups. We utilized intrahemispheric 
collagenase injection rat ICH model and MRI follow-up imaging up to 72h. 
Group 1 received tPA only, whereas Group 2 and Group 3 besides tPA received 
chromoglycate in single or double dose. Group 4 was used as a control having ICH, 
but receiving saline only. TPA-treated animals did not have significantly larger 
hematomas or hemispheric expansion even though been characterized by worse 
overall outcome. Application of chromoglycate in high dose mitigated detrimental 
outcomes present in the group being treated with tPA only, and diminished the 
extent of hemispheric expansion. This encourages further research to potentially 
establish “blind” thrombolysis concept coupled with concomitant application 
of MC inhibitors, as we could show that injurious tPA effects were successfully 
abolished by concomitant MC stabilization in experimental ICH scenario. 
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In the third study (III), we decided to develop a novel combined ICH + 
intraventricular hemorrhage (IVH) model in the rat as such a model does not 
exist besides the fact that approximately 40% of all ICHs in human patients 
are complicated by presence of intraventricular hemorrhage which is known to 
worsen prognosis. We utilized different blood volumes of 100-250 mL in modified 
autologous blood injection model to induce deep intrahemispheric ICH to establish 
a fully novel experimental approach of ICH followed by IVH. We performed 
1-week MRI follow-up and consistent neurobehavioral evaluation at 24 h, 48 h, 
72 h, and 1 week after hemorrhage. Using MRI, we identified the presence of 
hydrocephalus in all experimental subjects, and its progressive tendency during 
entire follow-up. The most prominent hemispheric expansion and the most 
pronounced hydrocephalus were present in experimental groups with >200 mL 
blood injection. This model was reliable and highly reproducible, demonstrating 
promising initial point for ICH+IVH experimental research.
These two novel treatment strategies established in our studies give promise 
for further refinements and potential applications in human patients. The novel 
ICH+IVH model we established in rat models may serve as an improved model 
for future experimental studies as it mimics human disease scenarios better than 
the existing models.
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1. REVIEW OF THE LITERATURE
1.1 Epidemiology of ICH
Intracerebral hemorrhage (ICH) represents 10-15 % percent (1,2) of all strokes, 
carrying devastating outcome and high case fatality which persisted over the past 
decades (3), and being characterized by the highest mortality rate of all strokes (3,4) 
with only less than 40 % of ICH survivors regaining independence (5,6).
ICH has an annual incidence of 10-30 per 100 000 population (7).This incidence (8) 
remained mostly unchanged within 30 years interval from 1980 to present time, being 
dominant in males, two times higher in Asian populations, and with a tendency to 
increase by age (5). Similar trend of stable incidence has been reported in one of the 
recent studies, limited to 45 to 60 years old population, with tendency to decline in 
older (1), being most prominent at age over 75. Most of the studies, however, report 
that incidence was steady, independent of age groups (9,10) even some showing 
increasing trends (11), which might be due to demographic and/or methodological 
differences. Incidence of ICH is notably influenced by subjects’ race, age, and sex, 
and could be reliably determined as a result of joined analyses of all these three 
factors. Individual variations in certain populations could be due to different degree 
of contribution of mentioned factors and potential environmental factor influence. 
ICH was more prevalent in males independent of age group (12)(13), while 
according to others, there were concordant results in population samples below the 
age of 65 and above this age, this difference became less apparent (7). Interestingly, 
sex differences in ICH affected subjects have been reported even as high as 2:1 in 
favor of male sex, in studies limited to smaller areas, without prior detection of sex 
dependent discrepancy in ICH risk factors (7), probably again influenced by racial 
and/or age structure of the defined population area. The data for the age below 45 is 
rather scarce due to the fact that ICH is a rather rare condition in this age group (14)
(15). Aging significantly influenced the incidence of ICH, represented by constantly 
increasing trends up to age of 85 (16,17)(18) probably due to increased presence of 
amyloid angiopathy, hypertension, and use of antithrombotic medications, while in 
population older than 85, ICH incidence showed decreasing or stable trends (18,19). 
Ethnicity also acts as an important determinant and contributes in defining ICH 
incidence, representing clear dominance in Asian populations (5), however not in 
the migrating ones (18), pointing out the potential strong influence of environmental 
factors. In the United States, ICH is more frequently present in Black and Hispanic 
populations (20).
ICH is likewise, a fairly common clinical condition in Finnish population, counting 
for more than 1,400 cases of ICH being registered every year, carrying devastating 
outcomes, with 41% of annual mortality, leaving 12% of patients institution-
dependent (21).
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1.2 Etiology and risk factors
Spontaneous or non-traumatic ICH appears either as primary or secondary. 
While primary spontaneous ICH emerges due to fine pathological changes of 
intracerebral vessels, clinically presenting as acute manifestation of small vessel 
disease, it secondarily may arise as a consequence of oral anticoagulant therapy, 
or on the grounds of other pathological structures in brain. Albeit hypertension 
is clearly recognized as the most prominent risk factor contributing to ICH in 
numerous studies (22–26), altering the structure of intracerebral blood vessels (27), 
cerebral amyloid angiopathy also plays important role in primary non traumatic 
ICH etiology (25,28). Hypertensive microangiopathy and structural reasons have 
been reported as dominant etiological factors of ICH in young adults, thus, defining 
hypertensive microangiopathy being a less common etiological factor compared 
to older population (29). Cerebral amyloid angiopathy, the second common 
cause of primary non traumatic ICH (30) is particularly present in elderly people 
(31), frequently associated with genetical mutations (32).
Life style has strong influence in ICH development. Dietary factors have role in all 
stroke types occurrence. Extreme body mass index is shown to be associated with 
increased risk of deep ICH, highly likely due to increased vascular pathologies 
underlying this condition (33,34). Smoking is the most significant risk factor for 
subarachnoidal hemorrhage (SAH), and an important risk factor for ICH (1.3 
times) (13,35). Contribution of psychosocial stress and alcohol intake have been 
also found as relevant risks for ICH (24). Alcohol consumption of more than 150 
g of ethanol per week causes three-fold risk increase of ICH, acting additively 
with hypertension, or as an isolated risk factor (36,37). The risk of ICH could 
be therefore significantly diminished if alcohol consumption and smoking are 
suspended and high blood pressure effectively treated (38).
Different therapeutic agents have shown important impact on ICH risks and 
overall outcome. Previous studies showed the importance of anti-platelet drugs 
as protective after ischemic stroke, nonetheless, they were related to higher 
risk of ICH, furthermore negatively affecting outcome (39,40). Utilization of 
oral anticoagulant warfarin was displayed as an important etiological factor of 
secondary non-traumatic intracerebral bleedings, being identified both in clinical 
(41,42) and experimental conditions (43). The increased warfarin use, critically 
affected the ICH incidence (10), whereas opposite findings were interestingly 
shown in population of Northern Ostrobothnia, Finland, such as decrease of annual 
incidence and warfarin-related ICH case fatality (44). Warfarin-associated ICH is 
found to be more common in patients with vasculopathies associated with chronic 
hypertension and cerebral amyloid angiopathy (45). The concurrent therapeutic 
application of warfarin along with serotonin-modulating antidepressants 
compared to warfarin alone, deleteriously affect the case fatality rate in spontaneous 
ICH (46). Similarly, secondary ICH cases were identified after application of 
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noval oral anticoagulants (47) when compared to warfarin demonstrating lesser 
risk for secondary ICH (48). Application of tPA as a theatment of acute ischemic 
stroke (49) leads to secondary symptomatic intracranial bleedings in 2-8% of the 
intravenously tPA-treated ischemic stroke patients (50,51).
Table 1: Increase of ICH risk due to various factors in patients with atrial 
fibrillation determined in a large patient population (52)
Intraventricular hemorrhage (IVH) often appears in neonatal period as a 
primary event (53), and is rare in adults without simultaneous ICH as the source of 
IVH blood (54). Approximately 40% of ICH event in adults are complicated with 
concomitant secondary intraventricular extension (2), which worsens patients’ 
outcomes (55).
ICH may also develop on the grounds of other structural pathological changes. 
Intracranial tumors (56), cavernomas, structural vascular anomalies such as brain 
or pial/dural arteriovenous malformations (57), or aneurysms (58). ICH was also 
described as a consequence of cerebral venous thrombosis, an uncommon cause of 
stroke (0.5% of all strokes), complicated with intracerebral bleeding in one third 
of cases(59). Further causes include coagulation disorders, moyamoya disease, 
vasculitis, and post-carotid endarterectomy hyperperfusion syndrome.
ICH risk factor
Hypertension
Increased age (>75)
Female sex
Smoking
Diabetes mellitus
Peripheral arterial disease
Prior ischemic stroke
Prior intracranial hemorrhage
Ischemic heart disease
Aspirin
Warfarin
Dabigatran (NOAC)
Risk increase of ICH (-fold) in AF patients
1.48
2.10
1.10
1.04
1.62
1.26
1.13
2.41
1.34
1.54
1.20 - 2.39 (depending on time in 
therapeutic range)
0.76
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Secondary ICH
 
1. Coagulopathies
Congenital coagulopathies (e.g. factor 
VII deficiency)
Anticoagulation therapy related coagulopa-
thy: Warfarin or NOACT 
Systemic disease related secondary coagu-
lopathy
2. Vascular malformations
2a Arterial wall anomalies
Arterial aneurysm
Moyamoya
Telangiectasia
2b Capillary junction anomalies
AV malformation
Dural AV fistulae
Cavernous malformation
2c Cerebral vein malformation
Developmental venous anomaly
 
3. Tumor related ICH
Primary tumor
Metastatic tumor
Neoplastic aneurysm
Tumor induced coagulopathy (DIC, anemia, 
thrombocytopenia)
Tumor treatment related ICH
 
4. Systemic disease related ICH
cerebral vasculitis (autoimmune disorders)
hepatopathy
sepsis
systemic disease related thrombocytopenia
5. Cerebral venous thrombosis
 
6. Drug addiction
i.v. amphetamine
other i.v. drugs
7. Other rare/unclassified etiologies
reversible cerebral vasoconstriction syn-
drome
Wernicke encephalopathy
endocarditis
hyperperfusion syndrome
pregnancy and post partum period
Primary ICH
1. Hypertensive angiopathy
2. Cerebral amyloid angiopathy
Etiology of non-traumatic ICH
Table 2: Etiology of non-traumatic ICH (2,60)
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1.3 Clinical presentation of ICH 
Clinically, ICH is associated with impaired consciousness, severe headache, 
nausea, vomiting, seizures, and focal bleeding localization-dependent neurological 
deficits. The decreased level of consciousness occurs highly likely due to 
joined events of disturbance of thalamic structures and/or reticular formation of 
brain stem (61), originating from raised ICP as the consequence of ICH. Large 
hematomas of any location might provoke immediate loss of consciousness and 
rapid death due to critically increased ICP, though small lesions located in posterior 
fossa can also cause fatal outcomes (62). More than 90% of patients present 
with high blood pressure levels on onset (> 160/100 mmHg). The autonomic 
nervous system disorders are often attributable to ICH, clinically displayed as 
tachy- or bradycardia, hyperventilation as well as centrally-induced fever and 
hyperglycemia (62). Onset of epileptic seizures after ICH is characterized as 
immediate (at the onset of the hemorrhage or within first 24h) or early (up to 30 
days after ICH onset) , described to be 4.2 % and 8.1%, respectively (63). Most of 
the seizures appear either on onset or within the first days after acute hemorrhage 
(64). ICH clinically presents as supra- or infratentorial. Supratentorial ICH can 
be recognized either as lobar or deep. Lobar ICH is localized in the cortex and 
cortical-subcortical junction regions, while deep ICH localization is limited to 
thalamus, basal ganglia, internal capsule, and deep periventricular white matter 
(65). Infratentorial ICH is defined as hematoma localized in brain stem and 
cerebellum. According to location, ICH types are shown to be etiology- and age-
dependent. Lobar ICH incidence is growing with aging (66), and it is shown to 
be associated with warfarin use, cerebral amyloid angiopathy, and prior history of 
ischemic stroke as independent risk factors. Warfarin therapy causes non-lobar ICH 
in majority of cases. Non-lobar bleedings are more likely present in patients with 
hypertension (67). Other secondary hemorrhage localization depends on initial 
location of structural pathological process (e.g. tumor) (68), and theoretically can 
exist in any part of the central nervous system.
Supratentorial ICH usually clinically presents as contralateral sensory-motoric 
deficits, commonly accompanied by higher-level cortical function disturbances, 
including aphasia (dominant hemisphere) or neglect, as well as gaze paresis 
and hemianopia (69). Infratentorial ICH is more associated with functional 
disturbances of brain stem, such as gaze disturbances, cranial nerve dysfunction, 
and contralateral sensorymotor deficits. In case of cerebellar involvement 
symptoms of ataxia, nystagmus, and dysmetria should be expected (69). Due 
to ongoing bleeding (70) and dynamical edema growth (71), neurological 
deterioration is frequently expected early after onset of symptoms and signs. In 
order to objectively follow patient’s neurological condition, several scales have 
been developed and are widely used in ICH patients especially in the acute phase.
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Glasgow Coma Scale (GCS) remains a well-determined parameter for follow-
up of ICH patients’ clinical condition and level of consciousness changes, being 
informative as an outcome predictor (72), and one of the crucial factors in decision-
making for invasive ICH treatment (73). GCS is highly predictive of mortality. In 
a study of Broderick et al., patients having GCS less than 8 and accompanied with 
large hematoma volumes (more than 60ml) had 30-day mortality as high as 91% 
(74). National Institutes of Health Stroke Scale (NIHSS) is a reliable and valid 
tool for measuring presence and severity of neurological deficits (75), commonly 
used in patients presenting with acute stroke, being useful for early prognosing and 
for serial assessments (76). It contains 15 items, and total score of maximum 42 
points. NIHSS therefore quantifies the key components of standard neurological 
examination (77). Scores over 20 points usually indicate severe paralysis and 
impaired level of consciousness. NIHSS is found to be relevant in assessment of 
30-day and 5-year mortality after ICH, as well as a long-term outcome predictor 
in surviving patients (78).
1.4. Imaging techniques of intracerebral hemorrhage
Neuroimaging plays essential role as a powerful diagnostic tool in patients with 
acute neurological deficits. The availability of imaging techniques provides 
excellent diagnostic possibilities for initial acute situation, but also acts as an 
irreplaceable mean for examining etiological determinants and performing follow-
up analyses.
1.4.1 Computerized tomography
Computerized tomography (CT) presents important first line imaging in acute 
ICH diagnosis in emergency department. It is cost/clinical information effective, 
with high availability, easy and rapid to perform. CT offers an accurate in vivo 
diagnosis (79,80) of intracerebral and intraventricular bleedings, providing 
data on type, exact localization, size, and severity of the lesion, furthermore 
facilitating follow-up of its natural history (81). Contemporary CT techniques 
include non-contrast CT (NNCT), perfusion CT and CT angiography (CTA). Non 
contrast CT is the dominant imaging technique in acute neurological situations, 
including hyperacute stroke, due to its high sensitivity (82), being as well feasible 
for approximate hematoma age determination (83). In the hyperacute phase, 
intracerebral hematoma is being detected as rather homogenous and smooth 
hyperintense signal in emergency NCCT scans (84), due to its high protein 
concentration. The globin protein, hemoglobin component present in hematoma, 
has a high density, which explains why intracranial hematomas are visualized 
as well-demarked hyperdense lesions in NNCT scans (85). Large hematomas 
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showing predisposition to emerge with presence of fluid level within first 48 
hours of symptom onset (86), which is determined to be highly specific for 
coagulopathies (86) and thrombolysis-related forms of ICH (87) being defined 
in literature as a hematocrit effect (88). During hematoma maturation, globin 
protein chemically degrades, which consequently leads to hematoma density 
decreases, progressing from hematoma periphery towards its core (89). NNCT 
is not considered suitable for long-term hematoma follow-up as hematoma 
resolution due to protein digestion eventually leaves just traces of hemosiderin 
(90), which are mostly not CT detectable and the remaining hypodensity cannot be 
distinguished from chronic lesions caused by other etiologies. CT angiography 
plays important role in defining the source of bleeding in ICH patients. It is a 
reliable diagnostic imaging procedure carrying high importance in recognition of 
cerebral vessel aneurysms and other blood vessel malformations, being nowadays 
considered almost as sensitive as digital subtraction angiography, which was long 
time considered the gold standard in diagnostics of vascular anomalies (91). The 
presence of contrast extravasation into hematoma region, being defined in CTA, 
known in literature as “spot sign” (92), described in about one-third of ICH patients 
(93), has been shown to be an important mortality predictor in primary ICH, 
predictive of hematoma expansion, which has been validated in many previous 
works (28,93–99) (See also chapter ICH outcome predictors). The phenomenon 
of pseudo-spot sign was noticed in patients with secondary ICH, where spot-sign-
like findings were not related to actual extravasation of contrast agent. Mentioned 
mimicking was classified as of vascular and non-vascular origin. Vascular spot-
sign mimicking, defined in specific cases, was referring to trombosed aneurysm, 
AVMs, and findings in patients with Moyamoya disease, whereas, non-vascular 
was attributable to calcific deposition (93).
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 1.4.2 Magnetic resonance imaging (MRI)
CT is still considered the gold standard for early ICH detection in emergency 
department. Even though MRI was previously reported being less sensitive than 
NNCT in hyperacute bleeding events detection (100,101), more recent research 
studies show the opposite (102). In earlier reports, MRI was speculated possibly 
insufficiently reliable for earliest ICH evaluation, validated to be sensitive enough 
in the period of 2.5- 5 hours after the bleeding event (103), although further 
reports shortened this time to 2 hours after symptom onset, even reported adequate 
and reliable T2* signal loss as early as 40 (104) or even 23 (105) minutes after 
bleeding.
Figure 1: Representative CT-images of etiologically and positionally various ICH
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ing, accompained 
by minor edema, 
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vascular changes
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with massive 
intraventricular 
bleeding 
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and secondary 
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Signal changes in MRI, in patients with presence of extravascular blood in 
brain parenchyma, are attributed to the presence of erythrocytes, clot matrix 
formation, cellular dehydration, and blood components brake-down products 
(100). MRI is indeed capable of depicting intracerebral bleedings in very early 
phase, which is however principally based on the magnetic susceptibility effect 
of deoxyhemoglobin. Deoxyhemoglobin is paramagnetic (106) which results in 
magnetic field inhomogeneities that consequently lead to local T2* relaxation 
enhancement. The signal change progresses from peripheral parts of hematoma 
towards its center, as previously shown in both animal (103) and human studies 
(107). MRI T2*-weighted sequences are sensitive to detect even minor bleeding 
events and therefore carry high clinical significance in detection of cerebral 
microbleeds (CMB), residues of possibly clinically silent, undiagnosed old 
intracerebral bleeding events (108,109), probably as a result of long-term deposition 
of iron in macrophages, long time after the initial bleeding occurrence (108). T2* 
is therefore considered a reliable sequence for ICH imaging in hyperacute phase, 
which was confirmed in experimental studies (110). T2* changes in the brain 
accurately correlate in chronic phase with iron overload followed by ICH (111). 
Another MRI technique, susceptibility-weighted imaging (SWI) is sensitive to 
magnetic susceptibility differences in tissues such as blood, calcification, and iron 
deposition. The superiority of SWI in detecting brain susceptibility changes when 
compared to T2* gradient-echo sequences relies on feature of SWI making use 
of both magnitude and phase information during image acquisition (112)  It is 
therefore providing fully valid and reliable in vivo measurement of brain iron 
deposition (113). It represents imaging modality bearing impeccable sensitivity 
to blood products and carrying marked capability for depicting various iron 
deposition dependent pathological conditions of central nervous system, including 
ICH (114). It was found especially powerfull for sophisticated diagnostics of 
AVM (115).
1.4.2.1 Diffusion-weighted imaging (DWI)
Diffusion weighted imaging (DWI) is a powerful MRI technique, uniquely 
providing information on brain tissue viability (116) with high ability to 
accurately identify the areas of acute brain ischemia. This sequence measures 
net displacement of water molecules caused by random Brownian motion. 
Those movements, defined as diffusion, are clearly restricted in a tissue affected 
by ischemia, as severe brain ischemia induces the intracellular shift of water 
molecules, which remarkably reduces the normal diffusion of water molecules 
into and out of cells. Reduced diffusion can be visualized on diffusion-weighted 
imaging (DWI) scans and quantified on apparent diffusion coefficient (ADC) 
maps (117). The brain tissue with non-restricted diffusion (high diffusion rate) 
carries high ADC values and appears bright on an ADC map. Oppositely, ischemia 
affected tissue carries low diffusion rates which emerge dark on an ADC map, and 
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is displayed by low ADC values. An exemplary DWI protocol would be highly 
sensitive to determine acute ischemic injury (118,119). While initially designed 
as imaging modality with high sensitivity in ischemic stroke, the significance of 
DWI has been also recognized in ICH studies (120). DWI, depending on the time 
of imaging after onset of bleeding, shows different signal patterns. Hyperintensity 
present in ICH core, followed by focal variable hypointensity, is a diffusion signal 
pattern related to hematomas in hyperacute phase (120). DWI sequences are also 
feasible for investigating features of perihematomal tissue. Low ADC values were 
described in the perihematomal rim in subsets of patients with hyperacute ICH 
(121), while high ADC values were present in hematoma-surrounding tissue, 
directly correlating to hematoma size, which might be explained as bleeding-size-
dependent vasogenic edema (122). In a recent study, DWI sequence performed in 
series of ICH patients, was found feasible to reveal the markers of small vessel 
disease including enlarged perivascular space, lacunae, cerebral microbleeds, and 
white matter hyperintensity (123). Concerning hematoma size, DWI is defined 
to correlate most accurately with hematomas detected by CT scans, while T2*-
weighted images carry the highest sensitivity but were shown to overestimate 
ICH lesion volumes when compared to CT (124,125). In a recent study, MRI 
was proven superior to CT in IVH diagnostics, shown to be 100% sensitive for 
detection of IVH, while CT failed to detect 3% of IVH cases (126).
The detected hematoma size overestimation in T2* sequences compared to CT 
scans was up to 19% in human studies (124), while similar findings were present 
in experimental conditions, with slightly higher overestimation level, showing 
high variability within 9-26%, however in this case not being compared to CT 
scans but to the amount of the blood injected into the brain parenchyma using 
the experimental double injection model (127). Concerning edema imaging, 
apart from DWI images, T2-weighted images are also found to be reliable in 
quantification of perihematomal edema, showing good correlation with histological 
findings in experimental conditions (128).
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Figure 2: Representative MR-images of various ICH etiologies
                  
1.5. ICH and IVH outcome predictors
Various predictive scores have been developed in recent years aiming at accurate and 
reliable estimation of ICH outcome. Numerous models for ICH outcome prediction 
have been described (8, 39, 40, 55, 124–133), taking into account three factors such 
as GCS, ICH volume, and the presence/absence of IVH as important ICH outcome 
predictors. Thorough the literature, GCS (thus, level of consciousness) is the well-
determined parameter always being a part of ICH outcome-prediction models. 
ICH-score (Table 3), one of widely accepted ICH-outcome predictor models, 
described by Hemphill et al (55), analyzed five independent predictors of 30-days 
ICH mortality, thus, this score was defined as a sum of those predictors. The GCS 
value was given highest priority on the scale, as it was determined to carry the 
most prominent influence to the overall outcome. This outcome measurement 
took into account the specific ICH locations associated with worse prognosis, 
such as infratentorial bleeding, as well as presence of IVH, which clearly acted as 
significant outcome predictor (see also Table 4 and Table 5).
SWI sequence showing 
numerous amyloid an-
giopathy based cere-
bral microbleeds
FLAIR sequence show-
ing well demarked 
inflammatory amyloid 
angiopathy based ICH
MR-angio image 
showing moya moya 
like stenosis of right 
internal carotic artery, 
accompained by typical 
collateral formation
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Cerebral microbleeds (CMB) are defined as very small and multiple foci of 
blood in the brain parenchyma, depicted as punctuate hypointense lesions both 
in T2* GRE and SWI , usually 1.5-15 mm in size, depending on underlying 
condition (139). Mentioned signal changes correspond to areas of hemosiderin 
breakdown products originating from prior microscopic hemorrhages, appearing 
in the impaired small vessel integrity scenario, due to hypertensive vasculopathy 
or cerebral amyloid angiopathy (139). CMB show various patterns, being rather 
small (1.5 mm on average, rarely up to 10 mm) in CAA, primarily localized at 
the gray–white junction often with a preference for the posterior lobes sparing the 
deep gray matter and cerebellum. Severe hypertension related CMB are usually 
bigger in size (typically 3-10 mm) involving the deep gray matter and deep white 
matter and may also be present in lobar areas (140). CMB are shown to be a 
relevant ICH outcome predictor (141). In other studies their role as a predictor 
was found significant only in patients using antithrombotic medication (142–144). 
When present in large numbers, they increase the possibility of ICH recurrence 
(145). The existence of T2* positive microbleeds are however reported not being 
significantly associated with new ICH and sICH after thrombolysis therapy (146).
Intraventricular bleeding extension (IVH), occurring in 35-40 % of ICH, acts 
as an independent predictor of ICH outcome (129, 146–148), and significantly 
increases mortality (150). Being compared (151), all IVH scores remained reliable 
if assessed within 6 days of the bleeding event, providing remarkable contribution 
in overall ICH outcome estimation, in ICH followed by ventricular extension.
Table 3: The system of points included in ICH score
ICH Score Points
2
1
0
1
0
1
0
1
0
1
0
0–6
Component
GCS score
3–4
5–12
13–15
ICH volume, cm3
≥30
<30
IVH
Yes
No
Infratentorial origin of ICH
Yes
No
Age, y
≥80
<80
Total ICH Score
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The extent of IVH and its contribution to outcome, was defined by various IVH 
scores (Table 4).
Table 4: IVH scoring systems. (152–155)
IVH scoring system
IVH score (Hallevi et al.) 0-23 points, ac-
cording to formula IVHS = 3 x (RV+LV) + III + 
IV + 3 x H*
 
Graeb score, Le Roux score and modified 
Graeb score
* RV - right ventricle score (0–3), LV-left 
ventricle score (0–3), III - third ventricle 
score (0, 1), IV - fourth ventricle score (0, 1), 
and H- hydrocephalus yes/no (0, 1).
Parameters being analyzed
The extent of bleeding in right, left, third 
and fourth ventricle, and presence of hy-
drocephalus.
The refined scores, based on more precise 
definition of intraventricular bleeding ex-
tent and degree of ventricular dilatation
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Study
Hemphill et al. (55), Portenoy et al. (129), 
Tuhrim et al. (130), Dixon et al. (131), 
Daverat et al. (132), Lisk et al. (133), Shapiro 
et al. (156), Mase et al, (135), Hallevy et al. 
(136), Fang et al. (137), Schwarz et al. (138), 
Qureshi et al. (8), Roquer et al. (39), Toyoda 
et al. (40) 
Diringer et al. (157), Tuhrim et al. (130), 
Phan et al. (158), 
Charidimou et al. (159), Kwa et al. (142), 
Gregoire et al. (143), Imaizumi et al. (145) 
Havsteen et al. (160), Romero et al. (28)
Leira et al. (161)
Roquer et al. (39), Toyoda et al. (40), 
Fan J-S et al. (162)
Zweifel et al. (163), Zhang et al. (164)
Löppönen et al. (165)
Kuramatsu JB et al. (166)
Kuramatsu JB et al. (167)
Gebel et al. (168)
Li N. et al. (169)
Albright et al. (170)
Parameter
Parameters most frequently recognized as 
ICH outcome predictors
GCS, ICH volume, Presence of IVH
Presence of hydrocephalus
Other parameters described in previous 
studies 
Cerebral microbleeds
Spot sign in CTA
Markers of inflammation (fever, neutrophil 
count, and serum fibrinogen levels)
Antithrombotic drugs
Copeptin
Elevated CRP value
Hyponatremia
Admission anemia
Relative edema
Matrix-metalloproteinases
Left ventricular hypertrophy
Table 5: Various parameters shown to act as important predictors of ICH outcome.
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Another possibly applicable prediction score for probability of ICH expansion 
was recently developed (171). The features of this scoring system are shown in 
Table 6.
1.6. Pathophysiology of ICH
1.6.1 ICH-mass effect and features of perihematomal tissue
The sequence of brain tissue injury events can be defined through processes of 
primary and secondary tissue injury. ICH-induced injury occurs primarily due to 
hematoma mass effect per se as it causes disruption of surrounding brain tissues, 
as well as due to its early growth. Those events represent inevitable mechanisms 
of primary brain injury. Very large hematomas itself, have tendency to cause 
significant neurological deficits, and the extent of neurological damage is related to 
hematoma volumes. Previous studies showed that hemorrhage size greater than 100 
mL in humans, caused significant intracranial pressure elevations (172), which was 
additively associated with poor prognosis and clinical outcome (74). The cranium is 
inflexible in adult humans and presents a definite space. Cerebrospinal fluid (CSF) 
volume in humans is measured to be about 200 mL (173). Therefore, the highly 
limited compensational potential of brain tissue in presence of such big lesions, 
usually accompanied with edema, explains the high mortality rates and devastating 
outcomes (174). The morphological changes and pathophysiological series of 
events following presence of ICH, could be explained by principles of the Monroe-
Kellie doctrine. According to this hypothesis, the sum of volumes of brain, CSF, and 
intracranial blood is constant. A shift in one of the mentioned compartments would 
be compensated by the decrease in one or both remaining two (175).  
Table 6: ICH expansion - prediction score. (171)
Points
0
2
 
2
0
0
1
2
0
3
1
0-9
Parameter
Warfarin use
No
Yes
Time to initial CT (h)
< 6
> 6
Baseline ICH volume (mL)
< 30
30-60
> 60
CT angiography spot sign
Absent
Present
Unavailable
Total
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Smaller hematoma volumes are more compatible with survival, however, still 
carrying a certain potential of leading to fatal outcomes. Nevertheless, hematomas 
smaller than 3 mL were uniformly related to good 3-month outcome. Further, with 
absence of early neurological deterioration, ICH volumes less than 10 mL showed 
clearly decreased odds towards absolute expansion (176). Early hematoma growth 
is a critical event causing significant neurological deterioration and contributing to 
the development of midline shift (177). Previously ICHs were thought to develop 
monophasically. Studies, which systematically analyzed hematoma growth by 
serial CT scans, showed presence of very early hematoma enlargement: in 26% 
of patients within one hour and in 36% within three hours after acute bleeding 
event, respectively (70,178). The early hematoma had also tendency to show later 
growth which occurred in 20-40% of clinical subjects imaged within the first 
day after ICH (179,180), while in other report, ICH enlargement was reported 
in 14 % of 627 ICH-positive clinical subjects, imaged within 24 h of bleeding 
onset (181). The hematoma growth within first 24 h was reported in detail in 
numerous studies (70,178,182). Presence of hematoma and its mass effect, as 
well as its early growth, would highly likely cause to the ischemic changes in the 
surrounding brain. Presence of perihematomal tissue damage was confirmed in 
numerous histopathological studies. Studies in experimental models have shown 
the presence of apoptosis and necrosis (183–188), autophagy (defined as relevant 
mediator in apoptotic pathways (189) (190–193)), and neutrophilic response (194) 
disturbing fine cellular architecture and representing existence of cellular death in 
ICH surrounding brain tissue.
Apart from histological findings, complex imaging studies recognized changes 
in perihematomal tissue. The hypothesis of possible presence of perihematomal 
penumbra has been widely speculated, and numerous studies provided 
contradictory findings (195). Perihemorrhagic tissue, possibly characterized with 
presence of oligemia and features of pending ischemia, as such representing 
potential perihematomal penumbra, would carry the remarkable potential to 
establish a novel therapeutic target for this devastating clinical condition (196). 
Diffusion and perfusion MRI were widely utilized in searching for answers 
about perihematomal penumbra concept. Schellinger et al (197) postulated that 
sign of hypoperfusion in perihematomal tissue more likely refers to diminished 
metabolic demands than to ischemic changes. Kidwell’s study similarly described 
presence of hypoperfusion in perihematomal ring, however, insisting that findings 
refer to ischemic changes due to DWI sequence findings and lowered ADC values 
(121). Same group of authors confirmed their previous findings in a different 
experimental setting using double blood injection model in rats (127). Some 
authors described perihematomal penumbra as a concept of DWI/PWI mismatch 
(198,199), described as a volumetric difference of tissue with preserved diffusion 
but compromised flow. Besides MRI, perfusion computed tomography (PCT) 
was also used for examining the perihematomal tissue, and akin to perfusion 
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weighted MRI, defined the presence of reduced perfusion in ICH-surrounding 
brain tissue (200,201). Positron emission tomography (PET) was also 
suggested to be relevant in possible perihematomal penumbra detection (202). 
Opinions about the practical value and relevance of PET technique in estimating 
perihematomal penumbra are still contradictory. While some authors find PET 
as the gold standard for the penumbra recognition in the perihematomal region 
(203), others remain neutral (204), or define MRI as the first choice technique in 
determination of ICH surrounding tissues features (205).
Apart from mechanical injury related to expansive influence and early growth 
of ICH, very complex reaction cascade originating from clot breakdown and 
coagulation products, leads to development of perihematomal edema (PHE) 
(206), already recognized as a factor influencing the overall outcome (168).
1.6.2 Mediators of secondary brain injury and perihematomal 
edema evolution after ICH
Brain edema formation represents the key event in secondary tissue injury 
after occurrence of ICH (207) and is defined as an increase of water content in 
brain tissue, consequently worsening the outcome by causing progression of 
neurological deficits and increased intracranial pressure. The mechanisms of brain 
edema formation are indeed complex. In initial phase, just after bleeding occurred, 
edema is highly likely a result of additive effects of hydrostatic pressure caused 
by hematoma and the process of clot retraction (207). Further edema progression 
occurs as an outcome of three interdependent mechanisms: (1) the coagulation 
cascade and formation of thrombin; (2) the inflammation sequence; and (3) the 
complement cascade along with hemoglobin toxicity.
1.6.2.1 The role of inflammation in PHE formation, and its 
contribution to secondary brain injury
Presence of ICH in the brain starts a complex set of inflammatory reactions. 
Inflammation after ICH consists of cellular component and is mediated by various 
mediators, forming the unique inflammatory cascade, making the treatment of 
ICH more challenging, however, also providing possible novel therapeutic 
targets for ICH. Inflammatory cascade is, therefore, a unity of two interdependent 
components, cellular and mediator component. Presence of neutrophils is 
determined as the crucial segment of cellular inflammatory response (208–210) 
after ICH. Activation and perihematomal region infiltration by polymorphonuclear 
leukocytes happens later than microglial activation, which is confirmed in 
experimental settings (211). Microglia is temporally the first cell line activated 
after ICH (212), otherwise representing primary immune effector cell type 
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within the brain, remaining normally in resting phase, but playing essential role 
in inflammatory responses, obtaining phagocyting properties, by gaining novel 
morphological and functional qualities after activation (211). Astrocytes also take 
important part in post-hemorrhagic inflammation, mostly by mediator secretion 
such as matrix-metalloproteinases (MMP) like MMP-2 (213) and MMP-9 (214) 
subtypes. Another type of resident cells in intact brain tissue, gaining activation 
following an acute stroke event, otherwise well-known in mediating anaphylaxis, 
are defined as mast-cells (MC). MCs are determined as a source of TNF-alpha, 
histamine, and other mediators, by which are getting directly involved in the early 
inflammation processes, consequently taking part in BBB integrity disturbance 
and brain edema evolvement (215).
1.6.2.2 Mediators in inflammatory cascade after ICH
The matrix metalloproteinases (MMPs) represent a family of more than 20 
structurally related, zinc-dependent endopeptidases which carry potential for 
degradation of collagen and other components of the extracellular matrix (ECM) 
(216). MMPs increase rapidly after ischemic stroke (217) and ICH (218) in 
experimental conditions. MMPs are enzymes normally present in brain tissue, and 
are important for adequate brain physiology, however, possibly showing deleterious 
effects and inducing secondary brain injury after ICH (219–221). Multiple cell 
lines, itself crucial contributors of inflammatory response, have been determined 
as MMP sources. MMPs were detected originating from macrophages, neutrophils 
(222), microglia, and astrocyte populations (223,224). It was previously shown 
that MMPs play an important role in promoting acute tissue- and BBB-damage 
(213,217,225,226), which is thought to significantly contribute to the progression 
of vasogenic component of PHE in experimental ICH (227,228). MMP-2 and 
MMP-9 subtypes are of special interest as they show specific tropism towards 
collagen IV, laminin, and fibronectin, which represent major components of the 
basal lamina around cerebral blood vessels (229,230). Numerous experimental 
studies showed increased presence of exactly these subtypes, MMP-2 (218) and 
MMP-9 (both in rat experimental models (214,218,231,232) and post-mortem 
human samples (233)), referring highly likely to their role in secondary brain 
injury following acute hemorrhage. Increased levels of MMP-3 and MMP-12 
subtypes after ICH were also identified, which gives them significant role to its 
pathophysiology (218), as increases in MMP-3 levels are directly correlated with 
mortality after ICH (226). MMP-3 and MMP-9 are also described having direct 
neurotoxic features (234).
Apart from proteases mentioned above, cytokines are another big group of 
molecular inflammation components, being of interest in ICH studies, due 
to their pro-inflammatory effects, and with their very probable contribution to 
secondary brain injury. They are a heterogeneous group of substances showing 
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strong interdependency, but tumor necrosis factor-alpha and interleukin-1-beta 
are separately defined to be highly likely directly involved in complex post-
hemorrhagic pathophysiological mechanisms (235). Their direct involvement in 
secondary brain injury and PHE formation was confirmed in experimental settings 
(236–239). 
1.6.2.3 Other mechanisms of contributing development of PHE 
and secondary brain injury
Activation of coagulation cascade is one of the fundamental episodes in brain 
edema development. Thrombin acts as a key integral of coagulation cascade 
initiating clot formation after bleeding event. It is identified as a neurotoxic 
modulator influencing inflammation and the edema formation in experimental 
scenario (240–244). Experimental studies also confirmed the irreplaceable 
role of complement cascade in formation of perihematomal edema (245,246). 
Cytotoxicity of blood degradation products and oxidative stress give significant 
contribution to secondary brain injury (247,248). Hemoglobin was proven to be 
neurotoxic and directly involved in caspase regulation, enzymes taking part in 
oxidative stress (249). Iron binding by deferoxamine was identified as a feasible 
approach in experimental conditions (250) with ability to be associated to favorable 
outcomes. Furthermore, overexpression of copper/zinc super-oxide dismutase-1, 
the enzyme owing the feature to reduce oxidative stress, ameliorated survival and 
functional recovery after ICH in an experimental setting (251).
1.6.3 The dynamics of edema growth
While initial presence of mass effect and early hematoma growth define events 
critically important for the clinical outcome, the development of perihematomal 
edema further deteriorates the outcome and makes the ICH treatment even more 
challenging (176). Dynamics and evolution pattern of PHE is found to be 
progressive and ICH-volume dependent (252,253). PHE is found to continuously 
increase within the period of 7 to 11 days after bleeding occurrence, with significant 
growth noticed as early as day one, tending to eventually reach the absolute value 
of more than two times compared to initial ICH volume (254). According to 
human studies with serial MRIs performed after ICH, the fastest edema growth 
was described at day two, while the edema growth peaks, in average, occurred on 
day 12. In studies by other groups, edema peaks were visualized as late as two 
(255,256) or even three (257) weeks after acute hemorrhage.
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1.7. Development of hydrocephalus
The presence of ventricular bleeding extension, IVH, appears as a complication 
in up to 40% of ICH cases (258). The wall of brain ventricles presents the 
area with low tissue resistance, opening the possible pathway for primary 
parenchymal bleeding to advance towards the ventricular system, by dissecting 
the surrounding brain tissue (69). IVH is clearly recognized as an important ICH 
outcome predictor (55). Intraventricular hemorrhage is furthermore complicated 
by hydrocephalus in up to 50% of IVH patients (157), being one of the key 
predictors of devastating outcome and mortality (157,259). Hydrocephalus is 
defined as a result of disparity between production and absorption of CSF, with 
successive accumulation of fluid in the cranial cavity and augmentation of the 
cerebral ventricles (260). The development of hydrocephalus has tendency to 
cause secondary brain injury through a complex inflammation cascade, ventricular 
distension which disturbs the integrity of periventricular fibers, and with increased 
intracranial pressure, which promotes more severe neurological deterioration. 
The hydrocephalus-induced secondary injury is therefore mediated by ischemic, 
mechanical, and metabolic-toxic disruptions (147,261–263). Pathophysiological 
analyses of periventricular tissue show damage to axons and myelin in the 
periventricular white matter, reactive gliosis, and occasionally neuronal injury 
and death (264–266). Del Bigio furthermore described more extensive damages 
affecting motor, sensory, visual, and memory systems due to engagement of the 
long projection axons, periventricular structures such as corpus callosum, and 
the fimbria-fornix pathway, that defines hydrocephalic brain dysfunction as the 
consequence of subcortical disconnection (267). Final ventricular enlargement 
after IVH is the result of presence of both obstructive and communicating 
hydrocephalus. The early obstructive hydrocephalus presents the potential life-
threatening complication if not being adequately treated (157), and is related with 
especially unfavorable prognosis and outcome, when involving third (268) and 
fourth brain ventricles (134). Hydrocephalus partially develops and furthermore 
evolves as the result of suffering of periventricular tissue structures, developing 
as a consequence of joined unfavorable events of direct intraventricular blood 
mass effects and inflammation cascade induced by blood and its degradation 
products (269). Furthermore, late, so called communicative hydrocephalus 
(270), takes important role in overall deterioration of brain ventricular system´s 
stability. It is being induced by compromised homeostasis of CSF circulation, 
related to presence of blood and its degradation products in the ventricular system, 
which leads to further advancing of inflammation, and consequently fibrosis of 
arachnoidea and Pacchioni granulations (269).
Secondary brain injury after IVH develops in a similar manner as in ICH 
without ventricular extension, being the result of combined effects of mechanical 
influence of intraventricular blood, more precisely mass effect and its toxicity. 
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Those result in ischemia, hypoxia, inflammation cascade activation, processes 
related to oxidative stress, and eventually decrease of cerebral perfusion pressure 
(271), however, furthermore complicated by impaired CSF circulation leading to 
pathophysiological sequence of hydrocephalus development (262). The role of 
iron in hydrocephalus development was recognized in IVH experimental models. 
Iron was defined as a contributor to ventricular enlargement and ventricular wall 
damage 24h after intraventricular iron injection (272–274), and its binding by 
deferoxamine in IVH experimental scenario, was found beneficial in terms of 
histopathological findings and outcome (273,275,276).
1.8 Identifying the therapeutic targets for ICH
ICH, with or without intraventricular bleeding extension, remains a devastating 
condition, causing high mortality and disability rates, still remaining a medical 
condition with very limited and underinvestigated therapeutic options, with only 
38 % of patients surviving the first year (277). The therapeutic procedures for ICH 
are roughly divided to conservative and surgical. In first aid (ambulance), initial 
management is realized through stabilization of airways, breathing, and circulation, 
furthermore focused to making quick diagnostic procedures and adequate triage to 
a neurological emergency unit. Additionally, all measures to diminish the risk of 
hematoma expansion, secondary neurologic sequalae or prolonged neurological 
deterioration should be performed (278). There is a high significance of executing 
aggressive initial care of ICH, which should be performed during the so called first 
¨golden hour¨, shown to be strikingly contributive to favorable outcomes (279). 
After initial hyperacute phase stabilization in emergency setting, conservative 
options of treating ICH predominantly focus on treatment of main etiological and 
risk factors, such as reducing high blood pressure (280) and correcting coagulation 
abnormalities (10). The efficacy of extensive high blood pressure treatment in 
hyperacute phase of ICH is widely accepted as one of the principal conservative 
ICH management strategies (280–282). This approach has been speculated, 
although antihypertensive treatment may diminish the risk and extent of the 
potential re-bleeding, to decrease the cerebral perfusion pressure, as deleteriously 
influencing the process of brain injury, if treatment is performed overaggressively 
(280). Nevertheless, a recent meta-analysis of major clinical trials showed that 
intensive decrease of systolic blood pressure in the hyperacute phase beneficially 
affected the outcome, and was confirmed as a safe therapeutic procedure (283). 
The significant lowering of blood pressure did not cause hypoperfusion in the 
border zones of the hematoma (284) and was not identified to be affecting cerebral 
blood flow (285). Utilization of warfarin and novel oral anticoagulants (NOAC) 
for various indications increased the prevalence of ICH in patients receiving these 
agents (47). In warfarin-associated ICH, anticoagulation must be vigorously 
reversed. Application of intravenous vitamin K and warfarin discontinuation 
seem however insufficient due to their slow effectiveness. Application of vitamin 
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K only would require from 12 to 24h to achieve reversal of warfarin-induced 
coagulopathy (286). Justifiably, utilization of prothrombin complex concentrates, 
recombinant factor VIIa, and fresh frozen plasma have been suggested (35,286–
289), as minimizing the delay of competent therapy application, was shown to be 
essential in successful emergency management of warfarin-related ICH (290). The 
optimal treatment for NOAC-related ICH is currently unknown (291), and there 
is so far no clinically validated NOAC-specific reversal agent (292), although 
development of these agents is underway. 
Intraventricular thrombolysis has been suggested as a treatment option for ICH 
complicated by intraventricular bleeding extension. It is a promising treatment 
option to promote intraventricular clot resolution after IVH, which was confirmed 
by the results of the CLOT III trial (293). The utilization of ventriculostomy 
catheter itself, was not found sufficiently effective for intraventricular clot 
reduction, however, was proven beneficial when intraventricular thrombolysis 
was applied in IVH patients requiring ventriculostomy (294,295).
Invasive ICH therapy modalities are surgical procedures of open craniotomy 
and surgical hematoma evacuation. Attempts of ultra-early hematoma evacuation, 
within 4 hours after symptom onset, were associated with high rate of re-bleeding 
scenario and were not proven to be outcome-effective (296). The profound 
meta-analysis of clinical trials published earlier than year 2006 and referring to 
conservative vs. surgical treatment of ICH, provided an odd ratio of 0.85 in favor of 
invasive technique (297). Mendelow et al. therefore designed the STICH I trial to 
address efficacy of surgical procedures. According to the results of STICH I trial, 
early surgical approach was not shown to be beneficial compared to conservative 
treatment, if performed 12h-24h from bleeding onset (298). The STICH II trial 
was thereafter designed to identify potential groups of patients who would gain the 
most benefit from invasive surgical treatment, such as IVH free patients, and those 
with smaller (10-100 ml) superficial lobar hemorrhage, being admitted within 48 
h from the symptom onset. Similarly, like in STICH I, surgical procedures failed 
to significantly contribute to better outcomes, even in these carefully preselected 
subgroups of patients (299). Surprisingly, in another smaller prospective study, the 
patients with subcortical and putaminal ICH less than 80 ml and with GCS more 
than 8 on presentation were associated with more favorable outcomes in subjects 
who underwent invasive surgical treatment (300). Alternatively, as a less invasive 
therapy option, techniques of minimally invasive surgery (MIS) for treatment of 
ICH have been developed. Auer et al. were the pioneers in hypothesizing potential 
benefits of minimally invasive endoscopic surgery for hematoma evacuation, in a 
sample of 100 patients, where favorable outcome and lesser mortality compared 
to patients who have undergone conservative treatment was limited to patients 
with smaller (< 50 ml) and with subcortical hematomas (301). A study by Zhou et 
al. analyzed MIS and conservative treatment options in 122 acute ICH patients, 
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and suggested minimally invasive stereotaxic puncture accompanied by clot 
lysis as possibly beneficial acute ICH treatment modality. Indeed, patients being 
treated with the mentioned procedure showed clear amelioration of GCS (302), 
qualifying this treatment modality being potentially feasible. Operative treatment 
of secondary ICH, developed on the grounds of other pathological condition 
(e.g. AVM, aneurysm, or tumor ), has been expectedly efficient (303–305), as 
the surgical removal of the underlying condition was achieved. The randomized 
ARUBA trial that included patients with unruptured AVM compared the risk of 
death and symptomatic stroke in patients having an unruptured brain AVM being 
treated conservatively or with combined conservative and surgical approach. The 
results of this trial nevertheless showed medical management alone to be superior 
during a 33-months follow-up period (306).
Concerning ICH therapy, there are numerous still ongoing clinical trials. Three 
not yet finalized trials STOP-AUST, STOP-IT, and SPOTLIGHT examine possible 
beneficial effects of different therapeutic agents (tranexamic acid and recombinant 
activated factor VII, respectively) on ICH outcome (307). Still ongoing MISTIE 
trial (MISTIE III started in late 2013), tries to profoundly answer whether the 
endoscopic evacuation followed by clot thrombolysis potentially promote more 
favorable outcomes and less mortality in ICH patients. The early results of 
MISTIE and MISTIE II, limited to supratentorial ICH, age 18-75, and GCS < 
13, suggested that blood clot removal from the brain could be done rapidly and 
considered safe, and initial result showed the potential of the mentioned MISTIE 
technique to beneficially influence the overall outcome and patients’ life quality. 
The mentioned technique is also associated with significant reduction of PHE 
(308–311). Similarly, still ongoing CLEAR IVH trial, so far provided encouraging 
results for utilization of similar technique in IVH clinical scenario (311–314). 
ACHIEVE trial was started in order to determine the potential beneficial effects of 
albumin in subjects with ICH, nonetheless, the trial was stopped due to problems 
of subject recruitment. Clinical trial of targeted-temperature management after 
ICH (TTM-ICH) (315), is aiming to show that TTM might be considered as an 
intervention to improve patients outcome, comparing the outcome differences of 
patients exposed to hypo- or normothermia. Another trial still recruiting subjects to 
determine the hypothermia effects in ICH patients is Trial of Cooling for Patients 
With Excel Cryo Cooling System in Intracerebral Hemorrhage (ICH) (CCSICH), 
postulating the neck cooling procedure as possibly beneficial in lowering ICP. 
Yet, INTERACT 2 (316) failed to show a significant improvement of primary 
outcome of death or major disability with early intensive treatment of high blood 
pressure, the trial defined this therapeutic approach to be safe and overall probably 
effective (317). Still ongoing ATACH II trial is aiming to more detailfully assess 
the safety and feasibility of aggressive hypertension treatment in ICH clinical 
scenario (318).
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Recognizing potential future therapy targets for ICH requires very extensive 
and profound further investigations. Many specific, experimentally proven-to-be-
beneficial therapeutic agents (e.g. tumor necrosis factor-alpha inhibitors (237), 
iron chelator deferoxamin (275,276,319–321), MMP inhibitors (322), free-radical 
scavengers (248), lymphocyte migration inhibitors (323), inhibitors of microglia 
activation (324), oxidative stress reduction (251), etc.) acting to the components 
specifically enrolled in mechanisms of complex cascade of late brain injury, could 
be the subject of further studies in clinical setting. 
1.9 ICH modeling - basic principles, advantages, and disadvantages
ICH represents a multifactorial and etiologically heterogeneous clinical condition 
(325), associated with high mortality and disability (133), without so far approved 
treatment, being limited to symptomatic therapy only. Therefore there is the 
urge to consistently and profoundly examine the underlying pathophysiological 
mechanisms of ICH, due to strong necessity to perceive novel therapeutic 
approaches which might be found effective for this detrimental clinical condition. 
This imposed tremendous inevitability to continuously seek innovative concepts 
of ICH animal modeling, aiming to implement unique and valuable knowledge 
about this unfavorable clinical scenario. The availability of novel imaging 
techniques, which could be accurately applied in experimental conditions, 
essentially contribute to development of representative experimental ICH models, 
and allow the accurate mimicking of clinical situation in controlled conditions, thus 
gaining immense translational accomplishments. Furthermore, the accessibility of 
sophisticated immunohistochemistry stainings, along with delicate and specific 
analytical microscopy, may more thoroughly enlight fine cellular features and 
crucial enzyme activities, including processes of repair and recovery, being overall 
influential to more extensive understanding of pathophysiological grounds of ICH. 
Undoubtfully, ICH experimental modeling carries enormous capability to provide 
information which is difficult to obtain in clinical settings. One of the limiting 
factors in clinical situation may be the critical condition of the patients (326), 
causing restrictions to extensiveness of imaging protocols (327) and detailed 
examination thus promoting experimental setting being a standard for examining 
certain clinically difficultly accessible pathophysiological features of ICH.
Although ICH animal modeling has numerous positive aspects potentially 
providing indispensable data for better understanding of complex ICH mechanisms 
(328,329) and establishing possible ICH therapeutic targets, modeling itself 
carries numerous limitations. Experimental stroke models are unfortunately 
often burdened with bias (330), and translational failures of experimental ischemic 
stroke models have been identified (331), being possibly similarly applicable to 
ICH modeling scenario. ICH is a disease more prevalent in the elderly populations 
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with multiple health problems (5), whereas experimental ICH studies are usually 
done in young and healthy animals, failing to reproduce the clinically often present 
age-increased comorbidity, and other ageing related influences. Additionally, 
experiments largely utilized male animals, even though human ICH attributes to 
both sexes. The ideal ICH model should carry the feature of being etiology-specific, 
easy to perform, reproducible, feasible in different animal species, and with a low 
variability. This might be practically difficult to achieve (325) in already complex 
experimental study design as each of the ICH models so far created carries its own 
strengths and weaknesses (332). Admittedly, no single up-to-date established animal 
model is found absolutely suitable for studying all the pathological features of human 
ICH (333). While hypertensive ICH models could be considered as most specific 
and relevant concerning etiological component, making them clinically applicable, 
their results are eventually poor due to immense fluctuation of size of hemorrhage 
(332). Other etiology-specific models have also been established, such as warfarin-
ICH model (43), in which hematoma growth and overall outcome could be reliably 
correlated with coagulation parameters. Genetically modified animals, mostly mice, 
are shown to be beneficial in defining the mechanisms of injury following ICH 
(334). The future tendencies in ICH model development should be nevertheless 
focused towards the establishment of animal models successfully and accurately 
mimicking pathophysiologic processes that lead to spontaneous ICH, hematoma 
progression, and the tendency of bleeding recurrence occurring in humans (335).
Various animal species have been used in ICH modeling, with clear predominance 
of rodents-mice and rats (43,188,194,209,214,336–344). Rodent models are 
highly likely dominant animal models in future ICH translational research, their 
predictive value being somewhat decreased due to relative scarcity of white matter 
in rodents when compared to human brain (334). ICH models were however 
successfully established using other animal species. Primates are rather rarely 
used in ICH modeling as they are expensive and difficult to maintain, however, 
some representative ICH primate studies have been performed (345,346)., Besides 
primates, experimental studies of ICH utilized canine (347–349), feline (350,351), 
and lapine (352–357) models. Lapine models seemed more constructive in terms 
of costs and housing. They were found suitable for studying fine surgical techniques 
such as minimally invasive therapeutic approaches (354,355) as well as acute brain 
injury mechanisms (332). Porcine models (319,321,358–360) are nowadays most 
utilized large animal models in experimental ICH research. They carry significant 
translational potential. The white matter distribution pattern shows great similarity to 
that in human brain. Secondly, porcine ICH models carry advantage of bigger brain 
size (about 40 time larger than rats´ brain), entitling their feasibility for examining 
different surgical procedures. Porcine models are nevertheless carrying the burden 
of limitations, similar to other large animals, mostly related to housing difficulties 
and ethical issues (332,361). 
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1.9.1 Rat models of ICH and IVH
1.9.1.1 Autologous blood injection model of ICH
Autologous blood injection model was developed as a technically rather simple 
way of inducing ICH in deep brain tissue. This model utilizes easily accessible 
own peripheral arterial blood of the experimental animal. Animal’s own blood 
in various volumes is administered to predetermined brain regions using precise 
stereotaxic technique. These deep brain injections were shown to be more feasible, 
whereas cortical injections showed tendency to cause subarachnoid hemorrhage 
and therefore inconsistent hemorrhage volumes (362). The very first attempt of 
arterial whole blood application into the brain tissue, using donor animal was done 
by Ropper et al (363), thus providing rather poor results due to modest feasibility 
and unacceptably high variability. Another limitation was that experimental setting 
in which blood was taken from the donor was highly prone to inflammation which 
is absent in clinical scenario. Early starts of autologous blood injection were 
established in the 1980´s, when for the first time Bullock and Mendelow (364,365) 
utilized own whole arterial blood of experimental animals for ICH induction. They 
created a model, where stereotaxically attached cannula was connected to either 
femoral artery, while effects of consequent changes of intracranial pressure (364) 
and cerebral blood flow (365) have been systematically followed. The authors, 
however, reported high variability of hematoma volumes, probably due to inter-
animal blood pressure variations. Bullock´s and Mendelow´s model establishment 
was modified by Nath et al. two years later who performed controlled injection 
of different blood volumes, injected stereotaxically, consequently leading to 
different hemorrhage volumes, responding well to the blood volume injected, 
under constant blood pressure conditions (366). The authors suggested that fixed 
pressure of 100 mmHg used in this study correlated well with the mean arterial 
blood pressure in human subjects. However, the constant pressure acted as a 
limitation factor for model’s reproducibility and its translational potential, as the 
blood pressure values were prone to variations. Almost ten years later, Yang et 
al (367) made a further modification of the pre-existing model, by utilizing a 
microinfusion pump, obtaining the possibility of injecting the arterial blood into 
the basal ganglia, in precontrolled constant time intervals. Accordingly, the model 
could be evaluated as reliable, nevertheless, this concept raised further issues 
of hemorrhage extending to undesired compartments such as needle pathway, 
ventricles, and subdural space. The operative procedure of inserting a catheter 
into the femoral artery itself caused, certainly minor, non-ICH induced disability, 
which could negatively influence the overall outcome (328). In order to avoid 
the vertical blood flow along the injection needle pathway, another group of 
authors modified the needle injection to 20 degrees (368). The issues of Yang´s 
approach were partially overcome by establishing the double-injection model in 
rats (344), which was replicated in mice (369) and which presented the technical 
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modification of initial autologous blood injection model. The blood injection was 
divided into two phases, which diminished the blood retraction from the skull burr 
hole along the needle path, and into subdural compartment. This however created 
other challenges, due to two injection times, as first injection resulted in blood clot 
formation, which led to eccentric elongated hematoma shape being present in white 
matter due to second injection, and the tendency of clot formation was generally 
increased (328). Other authors defined this model as rather successful (370), due 
to the fact that unwanted bleeding extension to subarachnoid space occurred in 
only one out of 13 animals. Further modification of this approach was done by 
Ma et al., performing triple-injection model (371) in mice, obtaining the blood 
from orbital veins, nevertheless carrying similar limitations and technical issues. 
So far established models eventually clearly delineated a stable translational 
approach for reliable and reproducible utilization of autologous blood injection 
model principles in experimental scenario.
Autologous blood injection model highly likely substantially replicates the phase 
of initial massive bleeding event, occurring in hyperacute phase of ICH, rather 
reliably mimicking the sequence of pathophysiological processes that occur after 
extensive initial hematoma growth defined in humans (70), however limitedly 
taking into account the component of continuous bleeding progression (178,179), 
which commonly arises within the first 24 hours after acute onset of hemorrhage 
(70,178,182). This model is therefore suitable for studying onset of events and 
brain injury component occurring due to presence of the hemorrhage-induced 
mass effect, partially excluding the capability of mimicking later brain injury 
mechanisms related to prolonged bleeding, delayed edema progression, and 
inflammation cascade activation. The latter imposes the limitation of this model 
in predictive outcome evaluation, as the brain injury occurring after timely limited 
bleeding event, is unlikely as severe as the one occurring in clinical situation. This 
might result in more favorable outcomes (372), described in autologous blood 
injection model, which appoints its inferiority for long-term follow-up studies. 
Thereupon, due to similar reasons, this model is not considered suitable for 
examining therapeutic interventions to the course of bleeding, as the hemorrhage 
event is limited to the very moment of injection, and hematoma does not 
progressively expand over time. More benign clinical outcome after autologous 
injection model, such as absence of seizures (373), might also be related to 
previously mentioned reasons. 
1.9.1.2 Microballoon model of ICH
Another approach for studying the ICH mass effect was the establishment of 
microballoon ICH model (374). The inserted balloon inflation in the region of 
caudate nucleus expectedly induced an increase of intracranial pressure (ICP), 
thus CBF was shown to be reduced. This approach was however indeed very 
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limited to brain lesion originating from mass-effect only, not including the toxic 
effects of blood, disturbance of BBB, role of blood in complex sequence of PHE 
development, or inflammation cascade which plays an essential role in secondary 
brain injury. The similar experimental scenario was used in attempting to define 
the effects of mass removal to the overall outcome (375), yet the equivalence 
of surgical hemorrhage removal was challenging to reliably mimic, which was 
characterized as the fair limitation of this experimental approach (370).
1.9.1.3 Collagenase injection model of ICH
Another widely used experimental ICH model in rats, widely named as collagenase 
injection model, was established by Rosenberg et al. in 1990 (376). Authors used 
the proteolytic enzyme features of bacterial collagenase type XI or type VII to 
disturb the integrity of collagen-containing basal lamina of brain blood vessels, 
consequently causing hemorrhage. The initial experiments were performed by 
protease-contaminated collagenase XI, which was later replaced by protease-
free collagenase type VII. The enzyme was slowly infused by a microinfusion 
pump within a period of nine minutes. Collagenase injection caused bleeding, 
extensively lasting up to 4 hours, without presence of tissue necrosis. Hematoma 
evolution eventually culminated to peripherally necrosis-positive two-zone 
hematoma identified 24h after collagenase injection. The size of hematoma and 
the PHE size were clearly injected-collagenase-dose dependent, qualifying this 
approach as simple to perform, controllable, reliably reproducible, and adaptable 
to other animal species (377). The presence of fresh blood which was defined in 
up to 4 hours after collagenase injection in the initial setting, was confirmed in 
further studies using contemporary MRI techniques (341). Fresh blood elements 
were identified even 24 hours after collagenase injection, suggesting the presence 
of late re-bleeding phenomenon (378). In the bacterial collagenase ICH model, 
MRI findings correlated well with histological features such as neutrophil invasion 
into the perihematomal zone within 12 hours, depicting compact neutrophil-
cell band surrounding hematoma after 24h, and macrophage invasion within 
48h after hemorrhage induction (194). The collagenase model has been shown 
to successfully simulate bleeding-rebleeding phenomenon, often present in 
clinical scenario, affecting the integrity of BBB and disruption of extracellular 
matrix (379), therefore, possibly exaggerating the extent of post-bleeding 
inflammatory response and secondary brain injury, likely as a consequence of 
possessing proinflammatory and neurotoxic features itself (332,380,381). Both 
rodent models were nevertheless characterized with remarkable dynamic increase 
of pro-inflammatory cytokines and adhesion molecules (382). The above-
described collagenase properties might justify why tissue loss was greater after 
bacterial collagenase injection, when correlated to autologous blood injection 
model having comparable hematoma sizes (341). Moreover, the indicators of BBB 
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disruption, such as gadolinium extravasation were more prominent in collagenase 
injection model, referring to more notable BBB damage (341). 
Previous findings consequently correlated with the overall worse outcomes, 
justifying different recovery profile from the one after autologous blood-injection 
model. Delayed cellular death shown in collagenase model leaves a wider 
therapeutic window for possible interventions (383). Collagenase model rats 
showed good recovery potential, remarkably influenced by extensive rehabilitation 
(384). Interestingly, the features of neuroplasticity, which displays the key factor 
for functional recovery after ICH, illustrated by enhanced neurogenesis, dendritic 
plasticity, and branching suggestive of synaptogenesis, were more prominent both 
in perihematomal regions and contralateral hemisphere in collagenase model 
compared to whole blood injection in rats (383,385).
We can conclude that collagenase model represents an excellent experimental 
strategy for examining long-term effects of ICH and pathophysiological sequelae 
of rebleeding, moreover representing reliable translational design for examining 
possible therapeutic effects to secondary brain injury events, however clearly 
carrying the burden of, though modestly, contributing itself to injury events not 
being directly related to presence of hemorrhage, which presents the limitation 
of this model. 
9.1.4 IVH models
As primary isolated IVH is rather rare in adults (386,387), most of the IVH models 
were related to neonatal period (388). Some of the isolated IVH models, in adult 
subjects, have been described in various animal species, including rodents. It was 
rather challenging to obtain sufficiently large hematomas in ventricular system to 
persist long enough, so the valid translational approach of IVH could be achieved. 
This was especially difficult to achieve in large animals, due to phenomenon of 
blood “wash out” by CSF, highly likely due to its low concentration of coagulation 
factors (389) which imposed the utilization of pre-coagulated blood. This criterion 
was well met in canine (390) and porcine (389) models of IVH. In rat models 
of IVH, freshly collected autologous non pre-clotted whole-blood was directly 
injected into the ventricular system in most of the works (273,320,391,392), in a 
uniform volume of 200uL, using stereotaxic technique, similar to that in the ICH 
autologous blood injection model. The IVH in rats showed tendency to resolve 
7 days after hemorrhage onset (392). Some of the latest models tried to mimic 
the ICH with intraventricular extension, by modifying stereotaxic coordinates, 
however presenting with rather modest intraparenchymal bleeding component in 
size, and consequent absence of sufficient contribution of expected mass effect and 
other mechanisms of injury, causing no mortality and therefore being potentially 
related to inadequate translational potential (266).
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Outcome in IVH models was directly related to the volume of blood injected 
(389,393,394). The prolonged contact of ventricular system with blood induced 
specific tissue changes, such as triggering the inflammation cascade as well as 
periventricular edema and fibrosis (395,396). The presence of hydrocephalus 
was recognized in numerous IVH models, and its pathophysiological features 
and dynamics thoroughly examined, generating important constituent of 
consistent IVH modeling concept, contributing to their translational power, since 
it frequently complicates IVH in clinical scenario. Lodhia et al systematically 
evaluated hydrocephalus development and progression in a rodent IVH model 
(392), defining hydrocephalus reaching its maximum by the second day after 
bleeding event and persisting up to 8 weeks. In Pang´s canine model, presence 
of progressive ventricular enlargement was defined in 80 % of subjects, where 
significant hydrocephalus was detected as late as three months after onset of 
bleeding (395). Compared to previous experimental designs, porcine model 
of May Frank determined rather early resolution of hydrocephalus, at 6 weeks 
after IVH, detecting fully normalized ventricle volumes (389). The role of blood 
toxicity and its degradation products in pathophysiology of hydrocephalus was 
consistently analyzed in recent works. The deleterious role of iron in brain injury 
after IVH was previously observed, referring to direct brain tissue loss and 
hydrocephalus development (272,273,320,397). The intraventricular injection 
of thrombin (391) or lysed red blood cells (272) also resulted in enlarged brain 
ventricles and impaired CSF circulation, consequently leading to hydrocephalus 
development. Similar mechanisms were suggested in neonatal rodent models.
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2. AIMS OF THE STUDY
1) To determine the possible effect of decompressive craniectomy procedure 
as a possible treatment for hyperacute ICH, and its influence to dynamics of 
hemorrhage, PHE, and most importantly the functional outcome (Study I).
2) To evaluate the feasibility of decompressive craniectomy performed at different 
time points after ICH and its potential to affect fine tissue changes, mortality and 
neurological and behavioral outcomes (Study I).
3) To estimate the degree of possible deleterious effects of tPA if applied in 
ICH scenario, and examine the likelihood of “blind” rapid trombolysis without 
necessity of prior brain imaging (Study II).
4) To define the potential of beneficial effects of mast cell inhibitor chromoglycate 
to counteract potential harmful influence of tPA in ICH experimental scenario, 
through changes in neurological outcome, mortality, and analyses of histological 
and biochemical features (Study II).
5) To establish a novel experimental model of ICH with ventricular extension 
(Study III).
6) To systematically evaluate mortality, outcome, and dynamics of hydrocephalus 
development in the novel ICH+IVH model (Study III).
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3. MATERIALS AND METHODS
All experimental protocols were approved by relevant Finnish authorities 
(Eläinkoelautakunta – ELLA = Animal Research Committee) and all the 
experiments and imaging performed in Biomedicum Helsinki, within the 
laboratory of Experimental MRI and Stroke Research Unit. In all the studies, we 
strictly followed 3R principles (replacement, reduction, and refinement) in all 
animal experiments, and the data analyses were performed in a blinded fashion, 
masked to treatment allocation and neurologic outcome.
3.1 Animals, anesthesia, and physiological parameters monitoring
In all three studies, we used male Wistar rats (Harlan Nederland, Horst, The 
Netherlands) of standard weight range (300-350 g). Prior to surgery, animals 
were caged in groups of five. Succeeding surgery, rats were housed individually, 
in the post-operative recovery period, and during the whole duration of follow-
up. Animals were housed in strictly controlled temperature and air humidity 
environment with ad libitum access to food and water, in 12/12 hour light-dark 
cycle. General condition of animals was observed daily by trained personnel. 
Animals were anesthetized by application of intraperitoneal injection of ketamine 
hydrochloride (Ketalar, 50 mg/kg; Parke-Davis, Stockholm, Sweden) and a 
subcutaneous injection of medetomidine hydro-chloride (Domitor, 0.5 mg/kg 
Orion, Espoo, Finland). A PE-50 tube was introduced in the left femoral artery, in 
order to measure and control blood pressure (Olli Blood Pressure Meter 533; Kone 
Oy, Espoo, Finland), and the same catheter was utilized to obtain autologous blood 
(I), (III) and for blood gas analyses (II). Rectal temperature was upheld at 37 °C 
during the surgical procedures and whole imaging protocol, by utilizing a thermo-
regulated heating lamp and/or heating blanket. In all the studies, we systematically 
followed physiological parameters. Blood pressure and body temperature were 
measured in all the studies before the surgical procedure, immediately after 
operation, and after MRI imaging protocol. We also consistently performed 
measurements of blood pH, glucose, and blood gases (AVL OPTI, Rotkreuz, 
Basel, Switzerland) in (II). Body weight of the animals was measured before the 
start of experiment, and was tracked daily until the experiment termination in all 
three studies. 
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3.2 Experimental protocols:
3.2.1 ICH Models
In our studies, we used two methodologically distinct ICH models, autologous 
injection model (I and III) and collagenase model (II). 
According to previously described methodology of autologous blood injection 
(398), firstly the head of rat was tightly fixed into a stereotaxic frame. A midline 
scalp incision was made to disclose the calvaria of the skull. Moreover, coordinates 
for autologous blood injection were determined by using the stereotaxic apparatus 
(Stoelting Co., Wood Dale, IL). The burr hole, 1mm in diameter, was made using a 
dental drill, into the right side of cranium. While the initial methodology remained 
the same, coordinates varied depending on the study. Coordinates were 0.2 mm 
anterior and 3.0 mm lateral to the bregma, aiming to obtain representative ICH in 
the basal ganglia region only (I). In Study III, coordinates were modified, to reliably 
and repeatedly acquire the presence of both parenchymal and intraventricular 
bleeding component, thus coordinates were 0.26 mm anterior and 2.2 mm lateral 
to the bregma. A 27-gauge needle attached to a Hamilton syringe was inserted 
at 6mm depth (I) or 5mm depth (III), into the area of right basal ganglia. In both 
studies, before the blood injection, a needle retraction of 0.5mm was done in order 
to form a small pouch. Autologous blood, obtained from the left femoral artery 
was injected slowly, with average speed of 2 µL per second. The injected blood 
volumes were 75 mL uniformly (I), or depending on the group, 100-250 mL of 
blood (III). The needle was kept in place for an additional 3 minutes after blood 
injection was completed. Finally, the burr hole was sealed with bone wax, and the 
scalp was sutured.
In the collagenase ICH model (II), initial steps of skull preparation were done 
identically as in autologous blood injection model, thus instead of freshly collected 
blood, we slowly injected bacterial collagenase type VII (Sigma Aldrich, USA). 
The collagenase dose was pre-determined in pilot studies, and the dose chosen 
(0.37 mL of diluted 0.1U/ ml collagenase) induced hematomas of 70 ml-80 ml in 
size at 24 hours, which was related to roughly 50% mortality at 3 day follow-up, 
being equivalent to clinical scenario.
The analgesic drug buprenorphine (0.05 mg/kg, Temgesic, Schering-Plough, 
USA) was administered every 8 h after the surgery for the first 48 h (I, II, and III).
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3.2.2 Decompressive craniectomy (I)
We utilized previously established technique of decompressive craniectomy (I) 
in experimental scenario (399). In sterile conditions, under general anesthesia, 
followed by additional topical application of lidocaine to the skull´s bony 
surface, using the dental drill, we created a bone flap of 0.9 x 0.5 cm in size, 
in right temporal bone, moreover removing additional bone down to the floor 
of middle fossa, under microscopic control with microscissors. In addition, we 
opened the dura covering the frontal, parietal, and temporal lobes, in large cruciate 
incision, without evidence of cortical resection. Over the region of craniectomy, 
we accustomed the temporalis muscle and sutured the skin flap in place. Even 
though the procedure was aimed to be accomplished in fully sterile conditions, we 
additionally administered antibiotic ceftriaxon (Ceftriaxone Copyfarm, 50 mg/
kg, Oxifarm Generics, Odense, Denmark) due to increased infection risk being 
related to extensive and demanding surgical procedure (I).
3.2.3 Pharmacological protocols (II)
The animals in Study II were assigned in different groups based on the treatment 
applied. One of the groups was without treatment and served as the control group, 
while the other three groups received 10 mg/kg of intravenous tPA (Actilyse, 
Boehringer-Ingelheim, Ingelheim, Germany, 10% bolus (0.3 mL) and 30-minute 
infusion (2.7 mL), n=33) immediately after ICH induction. Two out of three tPA 
groups received 100 mg/kg of i.v. chromoglycate (Sigma-Aldrich, Steinheim, 
Germany, 1 mL), a MC stabilizer, immediately before the tPA bolus (low-dose-
chromoglycate group), which was readministered after 60min in high-dose 
chromoglycate group, see also Figure 1.
3.2.4 The assessment of hematoma volume, hemispheric 
expansion, and dynamics of hydrocephalus using MRI
Depending on the imaging protocol, the evaluation of both hematoma volume and 
hemispheric expansion was performed in all the pre-defined follow up points, in 
all three studies. In order to reliably define the size of hemorrhage, we utilized 
specific signal intensity change, in highly sensitive T2*-weighted images. This 
included the manual tracking of hematoma boundaries using relevant software 
(Paravision, Bruker BioSpin, Ettlingen, Germany), from each MRI slice, whereas 
the delineated surface area representing hematoma was multiplied by the slice 
thickness and all the values finally summed to yield total hematoma volume (I, II, 
and III). 
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We used the same MRI sequence as the ground for calculating hemispheric 
expansion. We calculated the hemispheric expansion expressed as the percent of 
volumetric difference between the right hemisphere, affected by hemorrhage, and 
the intact left one. Firstly, we separately determined the total volumes of right 
and left hemispheres, and then enumerated the percent of hemispheric expansion 
according to the formula (right hemisphere volume/left hemisphere volume 
-1) x 100 (I, II, and III). We also evaluated the presence and the dynamics of 
hydrocephalus growth (III). During the whole follow-up period, we repeatedly 
calculated ventricle volumes, using T2-weighted sequences, starting 4 mm 
caudally of rhinal sulcus. In the same manner as above, all the values were 
summed to yield the total ventricular volumes.
3.2.5 MRI protocols
Imaging protocols were performed by 4.7 Tesla MRI (PharmaScan, Bruker 
BioSpin, Germany) with a 90-mm shielded gradient capable of producing a 
maximum gradient amplitude of 300 mT/m with a rise time of 80 microseconds. A 
linear birdcage radiofrequency coil with an inner diameter of 38 mm was utilized 
(I, II, and III). Experimental design included T2* weighted MRI sequence in all 
the studies. T2*-weighted images encompassing the whole brain were acquired 
with a fast-low-angle shot (FLASH) sequence (repetition time 350 ms; echo time 
10 ms; flip angle 40; matrix size 256 x 128; field of view 40 x 40 mm; number 
of averages 4; 14 slices; and slice thickness 1 mm) (I, II, and III). Additionally, 
to reliably evaluate ventricular volumes, coronal T2-weighted images were 
acquired with rapid acquisition using a relaxation enhancement (RARE) sequence 
(repetition time 3000 ms; effective echo time 60 ms; rare factor 8; matrix size 
256 x 192; field of view 40 x 40 mm; number of averages 6; 14 slices; and slice 
thickness, 1 mm) (III). 
3.2.6 Neurological evaluation
Neurological performance was systematically scored at days 1 and 3 after ICH 
(I, II, and III), and additionally after day 2 (II) and day 7 (I and III). We utilized 
an 8-point-scale (0: no deficit; 1: contralateral forepaw paresis; 2: 1+decreased 
resistance to lateral push, yet no circling; 3: 2+circling to the contralateral side; 
4: falling to the contralateral side; 5: rolling; 6: no spontaneous walking with a 
depressed level of consciousness; and 7: death). 
3.2.7 Behavioral outcome evaluation
The assessment of behavioral outcome evaluation was based on the SHIRPA 
(400) protocol (Table 7) and was performed blindly from video records, collected 
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in the same time frame as neurological evaluation. Behavioral outcome rating 
started with a startle reflex test by a sudden hand-clap 15 cm above the rat’s head. 
Then the animal was grasped gently by the tail, held 30 cm above the bench top, 
parameters of positional passivity, trunk curl, trunk curl direction (right or left), 
and forelimb tension and flexion were evaluated (see also Table 7). Moreover, the 
animal was lowered to close above a pole grid, and visual placing, together with 
forepaw grasping of the pole, was evaluated. Next, the animal was allowed to grip 
the grid with its claws, a gentle horizontal backwards pull was applied, so the grip 
strength could be assessed. Forepaw flexibility was checked on a smooth surface. 
Then, the animal was allowed to grasp a horizontal beam by its forelimbs, and the 
grasping, together with the beam maneuver, was recorded. Thereafter, a further 
set of evaluations included animal’s activity in a viewing jar (a glass cylinder 10 
cm in diameter), where animal was followed and recorded for 2 minutes, and its 
body position, spontaneous activity, and possible behavioral abnormalities and 
eccentric body positioning were estimated according to a scoring scale.
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test or posture scoring scale
startle reflex
0 none
1 backward flick of pinnae
2 jump ≤ 1 cm
3 jump > 1 cm
positional passivity (held 
by tail)
0 no struggle
1 slow struggling by hind limbs, occasional 
trunk curl
2 strong struggling by hind limbs and rotation 
of the shoulder
trunk curl (held by tail) 0 absent1 present
trunk direction
1 left curl
2 right curl
3 left and right curl
visual placing response
0 none
1 upon nose contact
2 upon vibrissa contact
3 before vibrissae contact
4 early vigorous extension 
forelimb extension and 
tension for right and left 
limbs separately
0 absent 
1 present
forepaw grasping for right 
and left limbs separately
0 absent 
1 present
grip strength for right and 
left limbs separately
0 none
1 slight grip, semi effective
2 moderate grip, effective
3 active grip
4 unusually effective
smooth touch reflex 
for right and left limbs 
separately
0 weak
1 flexible
body position in viewing jar
0 completely flat
1 lying on side
2 lying prone
3 sitting or standing
4 rearing on hind legs; repeated vertical leaping
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spontaneous activity in 
viewing jar
0 none, resting
1 casual scratching, grooming, slow movement
2 vigorous scratching, grooming, moderate 
movement
3 vigorous, rapid/dart movement
4 extremely vigorous, rapid/dart movement
head position in viewing jar
0 head down
1 normal head position
2 raised head
forelimb support (when 
body position in jar=3)
0 none
1 by left paw
2 by right paw
3 by both paws
catatonia-like behavior in 
viewing jar
0 absent
1 present
forelimb abnormal position 
in jar
0 none
1 left paw 
2 right paw
3 both paws
forelimb stereotypic in 
viewing jar
0 absent
1 present
head stereotypic in viewing 
jar
0 absent
1 present
stereotypic jaw-motion in 
viewing jar
0 absent
1 present
stereotypic rotation in 
viewing jar
0 absent
1 present
falling to the side in 
viewing jar
0 none
1 animal falling down on the left side (from 
vertical position) 
2 - on the right side
posture abnormalities in 
viewing jar sum of 7 previous tests
beam maneuver
0 active grip with hind limbs
1 difficulty to grasp with hind limbs
2 unable to grasp with hind limbs
3 unable to lift hind limbs, falls within seconds 
4 falls immediately
forepaw grasping on beam 
0 absent 
1 by left forepaw
2 by right forepaw 
3 by both
Table 7: SHIRPA - behavioral scoring scale (400)
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3.2.8 Tissue processing
Brain tissue processing included TUNEL (terminal deoxynucleotidyl transferase 
dUTP nick-end labeling) staining (I) and in situ zymography (II). At the end of the 
follow up period, all the animals were sacrificed by applying the overdose (60 mg) 
of sodium pentobarbital (Mebunat; Orion, Espoo, Finland), which was followed 
by immediate perfusion of still pulsating heart. Firstly, the midline abdominal 
incision was performed and the catheter inserted into the aorta and 200 ml of 
ice-cold saline (0.9 % NaCl) under constant pressure was infused. Secondly, a 
right atrium incision was made, which enabled blood drainage, and successful 
perfusion. After cardiac perfusion, the brains were rapidly harvested and dissected 
into 2-mm-thick coronal slices, one slice rostrally and three slices caudally from 
the site of intracerebral injection (I and II). In Study I, all the slices were positioned 
in 10 % formalin, followed by paraffin blocks embedment, and were cut into 4-μm 
slices. These slices were used for further TUNEL stainings (I). Additionally in 
Study II, each second slice was cut into two 1-mm portions (rostral and caudal). 
The rostral part was embedded into Tissue-Tek (Sakura Finetek Inc, Japan), snap-
frozen in liquid nitrogen, and kept thereafter at -80 C° until 8 µm sections were 
cut. The remaining slices were immersion-fixed in 10% formaldehyde and stored 
for further studies (I and II).
3.2.8.1 TUNEL staining (I)
Using the paraffin-block-embedded slices, two slices cut at the site of injection 
(first rostral and first caudal from the injection site) were stained with TUNEL 
(In Situ Cell Death Detection Kit, Fluorescein; Roche, Mannheim, Germany) 
for detecting DNA fragmentation and apoptotic bodies. The TUNEL assay was 
performed according to the manufacturer’s instructions. We assessed TUNEL 
stained slices with a light microscope (Axiovert; Carl Zeiss, Hallbergmoos, 
Germany). We counted TUNEL-positive cells in the whole hemorrhagic (right) 
hemisphere (including clot) and in the healthy contralateral hemisphere. Thereafter, 
we enumerated the TUNEL index, which represented a count of TUNEL-positive 
cells in the right hemisphere divided by the count of TUNEL-positive cells in the 
left hemisphere.
3.2.8.2 In Situ Zymography, immunohistochemistry, and image 
analyses (II)
Tissue activity of proteolytic gelatinase enzymes (most importantly MMP-2 and 
MMP-9) was assessed using in situ zymography (ISZ) as previously described 
(401). Cryosections were air-dried for 5 minutes in room temperature and 
washed with phosphate-buffered saline (PBS). All the sections were incubated 
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for 2 hours in 37°C covered with DQ-gelatin (0.1 µg/µL in reaction buffer, EnzChek 
gelatinase/collagenase assay kit; Invitrogen, USA). The sections were washed 
twice in PBS and once in dH2O after incubation. Control sections which showed 
blunted ISZ activity were incubated with MMP inhibitors ilomastate (500 µmol/L, 
GM6001; Millipore, USA) or tissue inhibitor of metalloproteinase-1 (500 nmol/L; 
R&D Biosystems, USA) 1 hour before and during incubation with DQ-gelatin in 37 
°C. Sections incubated without DQ-gelatin did not have fluorescent activity.
ISZ-sections were furthermore stained for the endothelial cell marker 
von Willebrand factor (vWF), and to estimate microvascular basal lamina 
disruption, adjacent sections were stained for Collagen IV. We utilized primary 
rabbit polyclonal antibodies from Abcam (UK, 19.5 µg/mL and 0.63 µg/mL 
respectively) along with Alexafluor secondary antibodies (Invitrogen). Equivalent 
concentrations of negative control rabbit IgG (Vector Labs, USA) did not show any 
specific immunostaining. 
For microvascular image analysis of the stained sections, we utilized pre-
defined regions of interest, determined from the perihematomal area and from 
respective areas of the contralateral hemisphere at 20x magnification with an 
epifluorescent Axioplan2 microscope (Carl Zeiss, Germany). 
The quantification of microvascular properties was assessed  by image analysis 
components of the Anduril workflow framework (http://csbi.ltdk.helsinki.fi/ 
anduril/ (402). As previously described microvascular gelatinase activity was 
depicted by automatically segmenting microvessels from the vWF-channel, 
and defining the relative brightness of each object from the ISZ-channel. The 
relative ISZ-brightness of each object was enumerated by dividing the object’s 
brightness by the brightness of a 20-pixel-wide ring surrounding the object. 
When the relative brightness is >1, the object is brighter than its immediate 
local background, indicating elevated activity. The mean gelatinase activity of 
the analyzed microvessels was further assessed for each hemisphere. In a similar 
manner, Collagen IV-stained microvessels were segmented automatically and 
counted for each hemisphere. All image acquisition and analyses were performed 
blinded to treatment group
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Figure 3: Schematic view of experimental protocols of studies I, II, and III
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3.2.9 Statistical analyses
In all three studies data were indicated as mean + S.D. for parametric data, 
medians for nonparametric data (also reported individually for each animal), or 
as proportions. Statistical analyses were carried out by SPSS (IBM, Armonk, 
NY, USA). In all the studies a 2-tailed P value of less than 0.05 was considered 
significant.
In study (I) repeated measurements were analyzed with 2-way repeated-measures 
analysis of variance followed by the Holm-Sidak post hoc test to detect changes 
over time or between groups. Changes in behavioral outcome related to the day 
of follow-up were assessed for each group with the Friedman 1-way repeated-
measures analysis of variance on ranks, succeeded by the Dunn’s post hoc test. The 
same test was utilized to label intergroup differences in behavioral outcome for a 
specific time point. Mortality rates were determined by the χ2 test followed by the 
Marascuilo procedure for comparing multiple proportions and were furthermore 
validated by multiple Fisher exact tests. As data sets in both study (II) and study 
(III) were nonnormally distributed, comparison of hematoma volumes (II, III), 
hemispheric expansion (II, III) and ventricular expansion (III), was accomplished 
at each time point using Kruskal–Wallis analysis of variance succeeded by the 
Dunn’s post hoc test. This test also served for comparing neurologic outcomes 
(II, III) and microvascular properties (II) between groups. Survival rates were 
analyzed with the log-rank test (II, III). 
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4. RESULTS
4.1 Study (I)
This study defined the effects of early craniectomy after ICH. It systematically 
assessed the mortality, neurological status, and behavioral outcome in rats with 
experimental ICH, undergone decompressive craniectomy at three different time 
points. It also analyzed fine changes in hematoma features, including changes in 
hematoma size and dynamics of PHE changes, using MR imaging.
4.1.1 Animals
The study included 61 operated animals, randomly allocated into three 
experimental and two control groups. Animals with ICH, but without 
craniectomy, were utilized as first control group. Another control group was 
done, to examine the effects of craniectomy procedure itself. All the animals 
(except second control group) received 75 mL of fresh autologous blood. This 
volume of blood was beforehand determined in pilot experiments to be causing 
about 50% mortality in rats, making it comparable to clinical situation, which 
provided strong and valid translational potential. Craniectomy was done in 
experimental groups at 1 h, 6 h, or 24 h after ICH; and in the second control 
group 1 h after anesthesia. There were no significant differences in physiological 
parameters between groups, while the least body weight loss was detected in 
craniectomy only group. 
4.1.2 Hematoma volume and hemispheric expansion
Craniectomy-only group was confirmed to be ICH- and hemispheric expansion-
free, referring to the fact that even being invasive, this procedure itself did not 
cause any clear MRI-detectable changes in brain tissue. Baseline ICH volumes 
were not different between groups. The 3-day hematoma size was significantly 
larger in no-craniectomy group, compared to treatment groups; yet no statistical 
significance concerning final ICH volumes was reached. A surprisingly low 
hemispheric expansion in ICH-only group was noticed, as dead animals (45 %), 
which highly likely had most prominent hemispheric expansion, and died from 
massive brain swelling, were not included, due to MRI data unavailability as a 
consequence of early mortality. Overall, the brain swelling reached the maximum 
on day 3 after ICH.
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Figure 4 in (I): Representative T2- weighted images. ICH was induced in all 
the groups in the same pattern, in the region of basal ganglia. Hyperintensity on 
images represents brain edema. Note also that the site of craniectomy is clearly 
visible in DC positive groups, yet the brain tissue remained uninjured after the 
procedure (no signs of cortical bleeding).
4.1.3 Mortality, neurological status, and behavioral outcomes
Mortality in no intervention group was as high as 45 %, hence, craniectomy 
significantly affected neurological and behavioral outcome. The earlier the 
craniectomy was performed, the better the outcomes were. No mortality was 
detected in the group having craniectomy as early as one hour after ICH, while 
10 % mortality had animals being treated by craniectomy 6 h after bleeding 
event. In late craniectomy group, 3 deaths occurred at early time points, all before 
the craniectomy was done. After craniectomy, nonetheless, no deaths occurred. 
Concerning improvement of neurological outcome, high significance was reached 
in all craniectomy groups compared to ICH-only group. Behavioral outcome 
was more favorable in early craniectomy groups, within the follow-up, in 1-hour 
craniectomy group improvement was noticed in 5 tests, 6-hour group improved in 
2 tests, while the ICH + craniectomy 24-hour group improved in 1 test only. We 
have also noticed deterioration in three tests in no craniectomy group. 
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Figure 5: related to study I: clear changes in mortality were noted as a result of 
early craniectomy, no deaths occurred in ICH DC 1 h group, while in 24 h group 
performed DC saved the animals surviving first 24 h after ICH.
Even though TUNEL staining differences between groups did not reach statistical 
significance, the lowest TUNEL index values were detected in ICH+craniectomy 
1 h, and ICH-craniectomy-24 h groups, which was related to low-apoptosis rate. 
4.2 Study (II)
4.2.1 Animals
This study included four groups of animals which underwent to different 
treatments. Three groups received tPA after collagenase-induced ICH, yet one 
group remained without any treatment and served as control. Two out of three 
tPA groups were given chromoglycate in single or double dose. There were 
no statistically significant intergroup differences in measured physiological 
parameters (mean blood pressure, rectal temperature, and blood pO2 and pCO2).
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4.2.2 Hematoma volume and hemispheric expansion
A single pre-determined dose of collagenase induced reproducible hematomas of 
similar initial volume in the right basal ganglia region. The presence of ICH was 
confirmed with MRI in all the animals after collagenase injection. The tendency 
of hematoma resorption was started to be visualized after 24 h, whereas MC 
stabilizer-chromoglycate did not significantly affect the pattern of hematoma 
development. Hematoma volumes did not show any statistical difference among 
experimental groups. Groups receiving adjuvant therapy of chromoglycate in both 
single and double dose apart from tPA, had detrimental tPA effects mitigated, thus 
shown statistically significant reduction of hemispheric expansion 24 h after ICH, 
compared to group receiving tPA only. This significance was present between 
high-dose chromoglycate group and tPA only group at the end of follow-up (72 
h after ICH), indicating the possible longer-lasting effect of MC stabilizer when 
applied in double dose.
Figure 6 related to Study II: Representative T2*-weighted magnetic resonance 
images from each group during follow-up.
4.2.3 Mortality, neurological score, and behavioral outcome
Mortality was 30 % in the ICH group without any treatment, while administration 
of tPA increased mortality up to 62 %. Application of MC stabilizer beneficially 
affected mortality, being 40 % in single and 10 % in double-dose-chromoglycate 
group. High dose chromoglycate fully reversed deleterious tPA effects after ICH, 
61
NOVEL THERAPEUTIC AND MODELING APPROACHES TO EXPERIMENTAL INTRACEREBRAL HEMORRHAGE
ACADEMIC DISSERTATION
concerning neurological outcome, recognized to be significantly better in this 
group of animals. Impaired behavioral outcomes in tPA only group, being worst 
at 24 h, were ameliorated by chromoglycate co-administration, resulting in more 
favorable outcome until the end of the follow-up period.
Figure 7 related to study II: Survival rate significantly improved after adjuvant 
MC stabilizer application, in ICH animals being initially undergone tPA treatment, 
which was especially prominent in high-dose-chromoglycate group.
4.2.4 Microvascular Gelatinase Activity and Basal Lamina 
Disruption
Application of tPA resulted in strong ISZ activation in both neurons and the 
microvasculature together followed by pronounced loss of collagen IV-positive 
vessels in the perihematomal area. Differences between groups, nonetheless, did 
not reach statistical significance.
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4.3 Study III:
4.3.1 Animals
This study aimed to establish a novel reproducible and reliable ICH+IVH 
model in rats, by comprehensively analyzing features of intraparenchymal 
and intraventricular hematomas, hemispheric expansion, development of 
hydrocephalus, as well as neurological and behavioral outcome in this experimental 
scenario. This study included 40 rats which were randomly allocated into 4 
groups, based on the quantity of blood injected (100-250 ml), and radiological 
and neurobehavioral parameters in each group were detailfully assessed. We did 
not find any statistical difference in physiological parameters (mean arterial blood 
pressure and rectal temperature) before and immediately after surgery between the 
experimental groups. 
4.3.2 Hematoma volumes and hemispheric expansion
Immediately after autologous blood injection, MRI-measured hematoma volumes 
were found to reliably correlate to the volume of the blood injected. Hematomas 
have shown decreasing trends during follow-up period in all the groups, mostly as 
a result of intraventricular bleeding component resorption. Hemispheric expansion 
peaked at 48h after ICH+IVH being most prominent in >200 ml, reaching statistical 
significance in comparison to groups with smaller hematoma volumes.
4.3.3 Ventricular volume
Ventricular volume increase was identified in all the groups and subjects. The 
ventricular volumes peaked on day 7 after bleeding event, being most distinct 
in > 200 mL groups. Statistically, both 200 ml and 250 ml blood-injection groups 
showed significantly larger ventricular volumes than 100 ml group during the 
whole follow-up period.
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Figure 8 related to study III: Representative T2* and T2 images of novel ICH+IVH 
model during 1-week follow up.
4.3.4 Mortality, neurological scores, and behavioral outcomes
The highest mortality was noted in 250 mL - 70 %, whereas mortality in 200 mL 
group was lower - 40 %. In both 100 ml and 150 ml groups, only one death per 
group occurred. The neurological scores showed a tendency towards dichotomy, 
lower scores were found in 100 ml and 150 ml groups, while clearly higher scores 
(partly from mortality which was equal to neurological score 7) were present in 
200 mL and 250 mL groups. Those groups showed statistical significance in all 
pairwise comparisons at all the follow-up time points. 
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The worst behavioral outcomes were present in 200 ml and 250 ml groups, both 
showing significant deterioration, so 250 ml group showed worse outcomes in 4 
behavioral tests than all the other groups at 24h after ICH+IVH.
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5. DISCUSSION
ICH remains a clinical condition with very limited therapy options, being 
associated with marked disability and high mortality rate. Ongoing research 
studies and various clinical trials continuously seek for effective treatment options 
for this detrimental clinical condition. 
5.1 Study (I)
The concept of decompressive surgery has been suggested at the beginning of 
the 20th century, and DC firstly suggested as a potentially effective therapy for 
massive cerebral edema in the 1950´s (403). ICP critically increases in massive 
stroke event. The crucial feasibility of DC as a highly invasive, but potentially 
life–saving procedure could be justified with the marked reduction of high ICP, 
hence halting development of coma and death. The latter is directly associated 
with capability of DC to restrain possible evolution of life-threatening downward 
herniations (uncal, cingulate, or tentorial), which frequently develop in high ICP 
scenario, consequently causing to death. DC was earlier suggested as an effective 
treatment modality of malignant ischemic stroke, both in experimental (399,404–
406) and clinical conditions (407). In the experimental design of malignant middle 
cerebral artery occlusion (MCAO), DC was critically beneficial for overall 
outcome and mortality. In another study by Engelhart, the time when DC was 
performed was defined as a critical factor since very early craniectomy (<4 h) 
was related to better outcomes (408). In three earlier multicenter, randomized, 
controlled clinical trials (HAMLET, DESTINY, and DECIMAL), DC was found 
to be a feasible therapeutic strategy in malignant ischemic stroke clinical scenario, 
and their pooled analysis showed that if performed up to 48h after malignant 
stroke, DC had significant potential to improve mortality and functional outcome 
of clinical subjects (409). The up to date information about potential effects of 
DC after ICH, however remains scarce. Previously, to our best knowledge, no 
experimental model of DC in ICH experimental scenario has been established. 
Until now, no clinical trials concerning potential effect of DC on ICH have been 
finalized. Nonetheless, at the moment, one trial (SWITCH) started by Swiss 
center, began patient recruitment in November 2014. Helsinki University central 
hospital is also participating in this clinical trial as a recruiting center (https://
clinicaltrials.gov/ct2/show/NCT02258919).
We hypothesized existence of similar pathophysiological mechanisms of herniation 
in malignant ischemic stroke and massive ICH, both associated with extensive 
brain edema, would entitle DC as a potentially feasible and beneficial therapeutic 
approach in hyperacute ICH scenario. As widely accepted ICH therapeutic 
protocols were limited mostly to symptomatic therapy and general management, 
there was an utmost urge to develop a reliable and reproducible experimental 
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model, which would create a promising basis for further clinical research. By 
using earlier established technique of autologous blood injection model in our 
laboratory (410), we firstly designed a pilot study aiming to identify the blood 
volume causing the mortality close to 50 %, being similar to one in clinical 
scenario. The subjects having hematomas related to such high mortality rate if 
left untreated were recognized as a suitable intervention group to demonstrate 
potential benefits of DC. Referring to previously shown more prominent benefits 
of early performed DC after malignant ischemic stroke (408), we aimed to 
analyze the possible differences in feasibility of DC, performed as early as one 
hour after bleeding event, up to 24 h after ICH. We therefore consistently analyzed 
the mortality, dynamics of hematoma evolution, and edema development in MRI 
images as well as neurological and behavioral outcome, at 1 h, 6 h, and 24 h after 
autologous blood injection and experimental ICH was realized. 
No deaths occurred in ICH-DC-1h group, which is clearly associated with 
marked feasibility of very early DC. In group where craniectomy was done 
6 h after ICH, one death occurred (10 % mortality), which might be explained 
by possible complication of repeated anesthesia yet being clearly better than 
mortality present in ICH group without DC (45 %). In ICH-craniectomy-24 h, 
all three deaths occurred before DC was even executed, pointing out apparent 
feasibility of early craniectomy approach. Once DC was done, no deaths were 
present in the same group of animals. Another interesting finding of this study 
was the presence of obviously smaller ICH volumes in all DC groups 72 h after 
craniectomy. The latter might be manifested due to lack of rebleeding episode and 
increased bleeding resorption capacity, as a result of dramatically lowered ICP on 
the ground of previously completed DC. The mentioned finding nevertheless did 
not reach statistical significance (P=0.065). Brain swelling peaked 3 days after 
ICH. The presence of rather modest brain swelling in group without DC should be 
critically addressed. This could be explained by missing data due to high mortality 
rate in this group (45%) and inability to include data of most severely affected 
subjects, which presents the limitation of this study. Survivors in this group had 
highly likely the presence of brain edema to most favorable extent in pre-defined 
experimental ICH scenario, being in these subjects insufficient to cause the 
lethal outcome. Effectiveness of early DC was confirmed through presence of 
improvements in behavioral tests during follow up, being most pronounced in a 
group with the earliest craniectomy (1 h). The same group was characterized by 
low TUNEL index, which might be speculated by early lowering of ICP which 
contributed to reestablishment of homeostatic conditions, before the irreversible 
apoptosis mechanism could be triggered. 
Our results have unambiguously shown the distinct benefits of DC being most 
pronounced in early craniectomy group, clearly ameliorating neurological 
outcome and rescuing all the animals from potentially lethal ICH. The 
demanding decision of decompressive surgery in case of malignant stroke event, 
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nevertheless appoints certain ethical issues. Potential implementation of the life-
saving early craniectomy after ICH, might, to certain extent, carry the potential 
to cause the outcome deterioration due to invasive decompressive surgery itself 
, leaving highly disabled subjects with questionably low quality of life, querying 
the definition of outcome which would be considered sufficiently favorable and 
determined as primary clinical objective (411). 
5.2 Study (II)
Patients having an acute ischemic stroke show clear benefit from application of 
tPA, if previously carefully and consistently selected based on clinical symptoms 
and initial CT imaging (412,413) and if treated in the pre-defined time-window up 
to 4.5 h (414). Out of the mentioned time window, the so called delayed tPA was not 
found sufficiently effective and its potential benefits were overwhelmed by high 
risks in these patients (415). Shortening the time of intervention (tPA application), 
defined as onset-to-treatment time (OTT), is shown to be critically influential 
on the final outcome (416–418), carrying overall potential to markedly affect 
patients´ average health benefits over lifetime, with each minute of OTT saved, 
granting on average 1.8 days of extra healthy life (419). Due to very strict criteria 
related to thrombolysis process, or because of fear of complications, relatively 
low percent of ischemic stroke patients is eventually undergone this potentially 
lifesaving procedure, which is especially pronounced in rural communities (420). 
One of the possible strategies to extend availability and feasibility of thrombolysis, 
could certainly be accomplished by introducing rapid on site treatment, which 
does not implicate the necessity of neuroimaging. This could be partly actualized 
by identifying the clinical features typically related to hemorrhagic stroke, being 
more often than ischemic stroke patients characterized with coma, neck stiffness, 
seizures, diastolic pressure higher than 110 mmHg, and vomiting (421). 
TPA represents a fibrin specific activator with capability to obtain the conversion 
of plasminogen to plasmin, promoting thrombolysis and salvaging ischemic brain 
by reestablishing the blood flow, hence both tPA and plasmin possess neurotoxic 
features been present in extracellular space (422). Even though being the only 
up to date approved drug for ischemic stroke, tPA is a molecule undoubtly 
carrying the ability to promote the various patho-physiological mechanisms 
involved in secondary brain injury and edema development after stroke. 
In previous experimental studies, tPA was identified to contribute to apoptosis 
(423), excitotoxic neuronal death (424,425), microglial activation (426), MMP-9 
upregulation (427,428), and other complex mechanisms mediating neurotoxicity 
and disturbing the integrity of BBB (429,430), overall representing detrimental 
tPA effects, being associated to worse outcomes. 
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Interestingly, the tPA involvement into BBB disruption is shown to be related to 
activation of thrombin activity (431). Apart from being one of the key components 
participating in coagulation, thrombin acts as neurotoxic modulator influencing 
inflammation and carrying noteworthy function in edema formation which 
was previously demonstrated in experimental scenario (240–244). Importantly, 
previous findings in our laboratory have shown that tPA is directly involved in MC 
activation (432), so that their stabilization was recognized as a potential therapeutic 
target to attenuate the adverse effects of tPA (215). MC are earlier recognized as 
a cell line having critical role in inflammation and immunological responses 
(433), acting as a mediator depository, which are released after activation (434,435) 
in a biphasic pattern. After activation, occurs the release of already accumulated 
mediators or de-novo produced ones (436). As MC are shown to have fundamental 
role in BBB integrity disturbance and edema formation, taking part in complex 
pathophysiology in ICH scenario (437), hence their activation following hyperacute 
bleeding event might be contributing to deleterious effect of tPA, identifying the 
MC stabilization as possibly feasible therapy approach.
We previously identified MC stabilization as a potential therapeutic target in 
both ICH and ischemic stroke in experimental conditions (215,401,410). Based 
on our previous findings, we hypothesized the potential beneficial effect of MC 
stabilization to so called “blind thrombolysis” (without preceding neuroimaging 
to exclude the theoretical presence of hemorrhagic stroke). We presumed that MC 
stabilization might be sufficiently effective to debilitate tPA-mediated adverse 
effects additionally convoluted by the mechanisms of both primary and secondary 
brain injury in ICH experimental scenario. This initial hypothesis was furthermore 
supported by recent experimental findings in mice, where intravenous application 
of tPA in two pathophysiologically independent ICH models, did not significantly 
cause hemorrhage deterioration (438). In our study, during 72 h follow-up period, 
application of tPA in ICH setting, resulted in neurobehavioral outcome deterioration. 
To mimic ICH, we used collagenase injection model, an excellent approach 
simulating the ongoing bleeding scenario, happening in clinical conditions, being 
especially suitable for examining the effects of different agents to the bleeding 
dynamics. Strikingly, the application of MC-stabilizer clearly ameliorated the 
outcome and led to significantly reduced mortality, demonstrating the ability of 
chromoglycate, potent MC stabilizer, to antagonize the tPA-mediated detrimental 
mechanisms. The results of ISZ show that proteolytic gelatinase activity was 
expectedly more pronounced in ipsilateral hemisphere, whereas the collagene-IV-
specific staining was less present. Interestingly, 72h after ICH, no clear difference 
was noticed between saline and tPA groups. This might be explained by the fact 
that 72h time point was over too late to detect the expected enzyme activity which 
might be also contributed by omitting the dead animals from the analysis, carrying 
potentially the most pronounced proteolytic activity of mentioned enzymes (see also 
Figure 9). 
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Figure 9: Analysis of proteolytic gelatinase activation and degradation of Collagen 
IV in the perihematomal area 72 hours after ICH. 
A Collagen IV staining was diminished and B gelatinase activity increased in the 
microvasculature of the ipsilateral hemisphere. 
5.3 Study (III)
This study aimed to establish a fully novel experimental model of ICH associated 
with simultaneous ventricular bleeding extension. Until now, only models 
of isolated ICH (188,344,366,374,376) or IVH (272,391,392,394,439–441), 
have been established. ICH+IVH represents a detrimental clinical scenario with 
undeniably devastating outcome and high mortality rate (2), missing the novel 
interventions, previously never been comprehensively experimentally assessed. 
Therefore, the strong necessity to determine this innovative approach in ICH 
modeling was imposed. We designed an entirely novel experimental approach, 
by modifying the pre-existing autologous blood injection ICH model, previously 
used in our laboratory (I). The blood injection coordinates of autologous 
blood injection ICH model (366,410) were modified, so the reliable ICH+IVH 
experimental scenario could be reproducibly achieved. We aimed to create the model 
carrying significant parenchymal bleeding component in basal ganglia region, 
furthermore complicated by intraventricular bleeding. Previous experimental IVH 
studies used injection of 200 mL of freshly collected unclotted blood, to induce 
isolated intraventricular bleeding (272,391). The primary isolated IVH is defined 
as a rather rare condition in adults (386,387), and is more related to neonatal 
period. Therefore, there was an obvious limitation of translational potential being 
carried by the mentioned models. We examined the effect of various hemorrhage 
volumes to development and dynamics of brain edema and hydrocephalus, as 
well as their influence to mortality and neurobehavioral outcome parameters. The 
mean total blood volume injected in different groups reliably matched the MRI-
measured total blood volume in T2∗-weighted sequences, strongly entitling this 
model as consistent and well reproducible.
Hematoma volume, dominantly intraventricular bleeding component showed 
marked decreasing trends during whole follow-up period thus parenchymal 
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bleeding component visually persisted as more stable. The similar phenomenon 
was noticed in earlier studies, IVH being resolved within one week, being 
explained by tendency of CSF to contribute to blood “wash out” from the ventricles 
(392). The borders between intraventricular and intraparenchymal bleeding were 
arbitrary and challenging to uniformly define, thus hematomas were analyzed as a 
summation of intraparenchymal and intraventricular components. 
The 200 ml of blood seemed to be a critical volume which crucially affected most 
of the factors analyzed in this study. The animals receiving > 200 mL of blood 
had marked edema, noticeable degree and progression of hydrocephalus, and the 
worst neurobehavioral parameters. We demonstrated hemispheric expansion 
increasing up to 48 h after ICH+IVH, after which it showed a tendency to decline. 
Simultaneously, hematoma volume showed a descending trend, implicating the 
hemispheric expansion growth being related to brain edema progress. The presence 
of hydrocephalus was detected in all the subjects, showing progressive trends 
during the whole follow up period, being markedly present in ≥ 200 mL groups, 
reaching statistical significance when compared to 100 ml and 150 ml groups. This 
could be explained by the more detrimental mechanical influence of larger volumes 
to homeostasis of brain parenchyma and ventricular tissue. This resulted in larger 
edemas, more pronounced deterioration of CSF, and mechanical periventricular 
and parenchymal damage probably being the sequelae of hematoma mass effect. 
Hydrocephalus highly likely developed as a combined result of immediate 
obstructive and delayed communicative hydrocephalus component. Obstructive 
hydrocephalus component originated from early impairment of CSF circulation, 
being previously shown (442), which often represents the reason for early mortality. 
Evolution of communicative hydrocephalus was highly likely contributed by 
complex secondary injury events, including inflammation and oxidative stress, 
furthermore complicated by previously suggested potential roles of thrombin and 
coagulation cascade activation (391), and deleterious effects of iron (272).
Expectedly, the worst neurobehavioral outcomes were identified in ≥ 200 mL of 
blood. Mortality rate followed the pattern of neurobehavioral scores, being most 
prominent in 250 ml group. In previous models of isolated IVH, which utilized 
200 mL blood injection (272,391), as well as in work of Chen et al, which aimed 
to ICH+IVH scenario, mortality was zero (266). This might be explained by lack/
modest size of ICH parenchymal component, which could be supposed to play 
essential role for potential fatal outcome, which is confirmed by our findings. 
71
NOVEL THERAPEUTIC AND MODELING APPROACHES TO EXPERIMENTAL INTRACEREBRAL HEMORRHAGE
ACADEMIC DISSERTATION
6. CONCLUSIONS
This thesis aimed to suggest novel, so far clinically unimplemented, therapeutic 
approaches which might be found feasible and beneficial for acute treatment of 
intracerebral hemorrhage. It also intended to describe pathophysiological features 
of complex ICH event and distinctly establish a solid base for further research in 
the field.
The capability of DC to serve as the therapy of choice in massive ICH has not 
been elucidated yet, and this certainly requires comprehensive experimental and 
clinical studies in future. Our results strongly suggested undoubtful feasibility and 
benefit of DC in experimental conditions, justifying the potential implementation 
of this procedure in future clinical trials and ICH therapeutic protocols. Our study 
presented the evidences which manifestly support the approach of earlier DC 
being related to more favorable outcomes, and created intriguing concepts for 
further studies.
Trombolysis treatment decisions have been normally entrusted by preceding CT 
or MRI imaging to prevent administration of tPA to patients with hemorrhagic 
stroke, most importantly intracerebral hemorrhage (ICH). This entails time-
consuming transfer of patients to the nearest stroke center, diminishing efficacy 
of thrombolysis. In this thesis, we defined that MC stabilization was feasible and 
powerful enough to effectively attenuate the additive effects of tpa-mediated 
deleterious events and the repercussions of ICH-mediated brain injury, possibly 
suggesting also that tPA acts in part through mast cell activation in this setting. 
These findings were of utmost importance as potential implementation of MC 
stabilizers into clinical protocols could theoretically authorize the opportunity 
to conduct the thrombolysis “blindly” without preceding, until now, compulsory 
neuroimaging. This would grant the indispensable prospect to shorten OTT, 
consequently bringing potentially tremendous impact to clinical outcomes in 
ischemic stroke patients, albeit the outcome of patients having hemorrhagic stroke 
at presentation would remain essentially unaffected.
In the final part of the thesis we designed a fully novel model of ICH+IVH, and 
for the first time applied autologous blood model modification, to establish a 
reproducible, reliable and highly predictable ICH+IVH experimental scenario. By 
applying 4 different blood-volumes and carrying out consistent MRI follow-up 
within one week after bleeding event, we achieved valuable translational approach 
thus laying ground for exploring novel pathophysiological features and innovative 
interventions for this extremely relevant clinical scenario.
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